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Pancreatic ductal adenocarcinoma (PDAC) is the 5th most common cause of death by 
cancer in the UK, accounting for 5% of all cancer deaths in the UK. Only 8% of the 
PDAC patients from all stages combined, survives for 5 years or longer. Late stage 
diagnosis combined with early cancer cell dissemination and poor response to 
current available treatments highlights the need for novel therapeutics tackling 
tumour growth and invasion.  
Previously, it has been shown that cellular plasticity during disease progression and 
the tumour stroma could contribute to cancer metastasis and resistance to therapy. 
Furthermore, progression in genetic sub-type classification of PDAC has shown 
differences in patient survival and response to treatment. However, PDAC cell 
plasticity and morphology in the presence of matrix has not been extensively 
addressed nor linked with sub-types thus far. Moreover, while 3D models are 
increasingly applied in order to mimic in vivo conditions more closely, the majority of 
current screening assays do not include components of the stroma and are based 
mainly on cell viability. In addition, well established genetic engineered mouse 
models (GEMM) and patient derived xenograft (PDX) are not cost effective or widely 
accessible for screening purposes. Understanding the behavioural characteristics and 
drug responses of PDAC cells with models mimicking the in vivo microenvironment is 
pivotal in developing novel therapies.  
To address the need for invasion models that can be used for screening, I have first 
investigated PDAC cell behaviour with the 2.5D model in vitro and selected a 
representative cell line for screening. Subsequently, I have developed and optimised 
a 3D co-culture spheroid screening platform to assess compounds for inhibition of 
PDAC invasion in the presence of pancreatic stellate cells. A select drug library with 
99 FDA approved compounds was probed for potential drug repurposing for PDAC 
invasion and selected for further validation. Together these experiments will provide 
us novel insight into the invasive behaviour of pancreatic cancer cells and identify 
potential novel molecular targets against PDAC cell invasion. 
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1.1. Pancreatic ductal adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDAC) originates from the exocrine 
compartment of the pancreas and is the most common form of pancreatic cancer, 
accounting for 95% of all pancreatic cancers (1). The term pancreatic cancer has 
therefore often been used for PDAC synonymously. The pancreas is an endoderm 
derived organ located behind the stomach in the abdominal cavity (2) (Figure 1-1). It 
plays an important role in nutrient metabolism and consists of an exocrine and 
endocrine compartment. The exocrine compartment comprises of ductal, acinar and 
centroacinar cells that are involved in the production of digestive enzymes and their 
transportation through a network of ducts into the duodenum (3). The endocrine 
compartment harbours the islets of Langerhans, which are small clusters of glucagon- 
(α-cells), insulin- (β-cells), somatostatin- (δ-cells), ghrelin (ε-cells) and pancreatic 
polypeptide- (PP-cells) producing cells that maintain glucose homeostasis (3). Given 
the exocrine compartment accounts for >90% of the pancreas, it is therefore not 
surprising that exocrine tumours are more common than endocrine tumours (3).  
Precursor lesions of PDAC include non-invasive intraductal papillary mucinous 
neoplasia (IPMN), mucinous cystic neoplasia (MCN) and the most common form 
pancreatic intraepithelial neoplasia (PanIN) (4, 5). A series of studies have reported 
that acinar cells might be the origin of PDAC through KRAS driven acinar-to-ductal 
metaplasia (ADM) transformation into duct-like cells with stem-cell like potential 
which could initiate PanIN formation, and progress to PDAC (6-10). However, recent 
findings have also suggested that transformation of ductal cells could potentially give 
rise to PDAC (11-14). It might not be surprising that through trans-differentiation or 
transformational processes that different cells of origin of the pancreatic exocrine 
compartment could give rise to PDAC in distinct manners.  
Pancreatic cancer commonly occurs in the head of the pancreas with 65% of the cases, 
in contrast to the 15% for occurrences in the body, 10% in the tail and 10% occurring 
in multifocal manner (15). Some pancreatic cancers can occur as primary tumours 
with a size of less than 2cm, which are found infiltrating into the surrounding tissues, 
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including lymph nodes and nerves, and are considered as locally advanced and 
unresectable pancreatic cancer (LAPC). Nevertheless, the majority of patients are 
diagnosed with metastatic disease. Pancreatic cancer spreads most commonly to the 







Figure 1-1. Anatomy of the pancreas. 
The pancreas is located in the abdomen behind the stomach and is connected to the 
duodenum. The organ consists of a ductal network connecting acinar cells that 
secrete digestive enzymes and pancreatic fluid to the duodenum. Islet of Langerhans 
are found embedded within the exocrine tissue and are responsible for glucose 




Pancreatic cancer is a lethal disease and is the 3rd leading cause of death by cancer in 
the US and 5th in the UK, with an estimated 50 000 and 10 000 new cases diagnosed 
every year in the USA and UK respectively  (1, 17). Despite extensive research and 
improved surgical techniques in the past three decades, the survival rates have not 
improved while the death rate for pancreatic cancer has increased by 0.4% per year 
(1). This is mainly due to lack of biomarkers for early diagnosis, high resistance to 
current chemotherapy and high propensity for early metastasis (18).  
The 5- year survival rate for all stages combined is only 8%, where most patients 
succumb to the disease in their first year of diagnosis (1). 10% of the patients are 
diagnosed with local disease (stages IA, IB and IIA), which are potentially curable with 
resection or are diagnosed borderline resectable (Table 1-1) (19). These patients 
have the best 5-year survival rate of 31.5%. Unresectable disease can be categorised 
in locally advanced and metastatic disease. About 29% of the patients are diagnosed 
with locally advanced pancreatic cancer (stages IIB and III) (19). In this situation, the 
cancer cannot be removed entirely by surgery due to its growth into or surrounding 
nearby major blood vessels, but has not yet spread to distant organs. These patients 
have an overall 5-year survival rate of 11.5%. 52% of the patients are diagnosed with 
metastatic disease (stage IV), which has a 5-year survival rate of less than 3% (19). 
The remaining 9% of the patients are either not diagnosed or were unable to be 
diagnosed for staging. These patients fall into the category of unknown staging and 
have a 5-year survival of 5.1% (19).  
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Table 1-1: Pancreatic cancer staging, stage description and related 5-year survival 
rate (20) 
Stage Stage description 5-year Survival rate 
0 Pancreatic carcinoma in situ or pancreatic intraepithelial 
neoplasia III (PanIN III). 
31.5% (19) 
IA No spread of the cancer outside the pancreas and has a 
diameter of 2cm or smaller. 
IB No spread of the cancer outside the pancreas and has a 
diameter larger than 2cm. 
IIA Spread of the cancer outside of pancreas, but not into 
major blood vessels, nerves, lymph nodes or distant 
sites. 
IIB Spread of the cancer outside of pancreas and lymph 
nodes, but not into major blood vessels and nerves or 
distant sites. 
11.5% (19) 
III Spread of the cancer outside of pancreas and into major 
blood vessels and nerves, maybe have spread to lymph 
nodes, but not to distant sites. 




 Risk factors 
Pancreatic cancer is more common in older people, with people aged 75 years and 
older accounting for 47% of the diagnosed cases (21). Furthermore, pancreatic 
cancer has an equal prevalence of 50% in both men and women (21). The disease has 
a rare incidence before age of 40, but the risk increases by 40-fold for developing the 
disease at 80 years old (22). Smoking has been the most well-established 
environmental risk factor for pancreatic cancer. Nitrosamines found in cigarette 
smoke has been reported to be potent carcinogens, exposing smokers to 
approximately a 1.74-fold increase in risk of developing pancreatic cancer (23). 
Several other risk factors such as obesity, chronic pancreatitis, diabetes mellitus and 
familiar history were linked to increased risk (24). Furthermore, it has been reported 
that African-Americans have the highest incidence rate of developing pancreatic 
cancer across different ethnical groups, whereas Asian/Pacific Islanders and 
American Indian/Alaska Native have the lowest incidence rate (19). 
 
 Molecular genetics in PDAC progression 
Genetic diversity is commonly found in pancreatic cancer, with frequent genetic 
mutations occurring in various genes such as KRAS (>90%), CDKN2A (95%), TP53 (75%) 
and SMAD4 (50%) (25). Furthermore, the progression from PanIN stages I, II and III 
to PDAC demonstrates that consecutive accumulation of these mutations results in 
accelerated progression of the disease (Figure 1-2) (26). Indeed, a genetic mouse 
model has demonstrated that expression of KRASG12D alone in the progenitor cells of 
the pancreas will develop PDAC, but only after long latency (27). However, 
inactivation of tumour-suppressive genes CDKN2A and TP53, and SMAD4 at later 
stages increases stepwise progression towards PDAC and metastasis (28-31). 
Moreover, telomere shortening has been reported in low-grade PanINs and 
contributes to chromosomal instability (32, 33). Subsequently, loss BRCA2, a tumour-
suppressor gene responsible for homology directed DNA damage repair, at later 
stages in sporadic PDAC could further contribute towards genetic instability and 
become susceptible for PARP inhibitors (34, 35).  
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The KRAS gene encodes two small GTPases, KRAS4A and KRAS4B, with the latter 
being the more dominant transcript in the pancreas (26). Inactive GDP-bound KRAS 
is normally activated by RAS guanine nucleotide exchange factors (RasGEFs), which 
are proteins that facilitate activation of KRAS by catalysing the exchange of GDP for 
GTP (26). Activated GTP-bound KRAS is able to bind to downstream factors and 
activate the downstream signalling pathway (26). The GTP-bound KRAS is then 
inactivated by RasGAPS, which are proteins that catalyse the hydrolysis of the KRAS 
bound GTP back to GDP (26). However, a point mutation in codon G12 of the KRAS 
oncogene (found in 98% of all PDAC cases) will prevent the formation of van der 
Waals interactions between KRAS and RasGAPs, which in turn impairs the ability of 
RasGAPs to hydrolyse the GTP bound to KRAS. This results in constitutive activation 
of downstream signalling pathways driving proliferation, anti-apoptosis, evasion of 
the immune response, remodelling of the tumour microenvironment and metastasis 
(36).  
Recent genetic sequencing and analysis efforts demonstrated that majority of the 
mutations (e.g. KRAS, CDKN2A, TP53, SMAD4) and additional mutations (e.g. KDM6A, 
RBM10, MLL3) found in pancreatic cancer patients can be grouped in 10 molecular 
mechanisms: KRAS, ROBO/SLIT Pathway, RNA processing, Cell cycle, DNA Repair, 
TGFBeta signalling, Notch Signalling, Wnt Signalling, Chromatin and SWi/SNF 
pathways (Table 1-2) (37). Furthermore, genetic studies on metastatic PDAC have 
found that genetic heterogeneity is not only present in the primary tumour, but also 
present in metastatic lesions, which might be required to successfully disseminate 
and colonise at distant sites (38, 39). Therefore, it is believed that multiple genetic 




Figure 1-2. Progression of acini into PDAC through cumulative mutations in onco- and 
tumour-suppressive genes. 
Activation of KRAS in acini gives rise to the development of PanIN. Inactivation of 
INK4A (CDKN2A) causes PanIN1 to progress into PanIN2. Inactivation of p53 and 
SMAD4 occurs during later stages and will accelerate the progression of PDAC 




Table 1-2. Gene mutations in pancreatic cancer categorised in 10 Molecular 
mechanisms. 
Molecular mechanism Mutated genes 
KRAS KRAS, MAPK4 
ROBO/SLIT pathway ROBO1/2, SLIT2. MYCBP2 
RNA Processing RBM10, SF3B1, U2AF1 
Cell Cycle CDKN2A, TP53, TP53BP2 
DNA Repair BRCA1/2, ATM, PALB2, ATF2 
TGFBeta Signalling SMAD3/4, TGFBR1/2, ACVR1B/2A 
Notch Signalling JAG1, NF2, BCORL1, FBXW7 
Wnt Signalling RNF43, MAPK2, TLE4 
Chromatin (histon 
modification) 
KDM6A, MLL2/3, SETD2 
SWI/SNF Complex 
(nucleosome) 




 Signalling pathways and therapeutic targets in PDAC 
KRAS belongs to the Ras GTP binding protein family (41, 42). Downstream effector 
pathways of KRAS include PI3K-PDK1-Akt, RAF-MEK-ERK, PLCε, Tiam1-Rac and 
RalGDS (Figure 1-3) (41-43). Not only has it been shown that KRAS play a major role 
in PDAC formation, but also that Ras sustains PDAC through regulation of anabolic 
glucose metabolism via MAPK and Myc signalling pathways (40, 44). Recent findings 
have demonstrated that activation of major KRAS downstream pathways were able 
to phenocopy KRAS driven PDAC in genetic mouse models. Targeted expression of 
PIK3CAH1047R, which encodes for the catalytic subunit of PI3K p110α, in the acini 
induced ADM, PanIN and subsequently PDAC (45). Furthermore, inhibition or 
deletion of proteins of the PI3K-PDK1-Akt pathway were able to suppress PDAC 
progression (45). Another study has demonstrated that targeted expression of 
activated BRAFV600E in the pancreas was able to induce PDAC (46). Moreover, 
pharmacological inhibition of the MEK demonstrated anti-tumour effects in PDAC 
cell lines (46). These finding demonstrate an important role of KRAS and its 
downstream pathways in PDAC progression and possibly therapy.  
Despite extensive research on KRAS inhibition, the first effective KRAS inhibitor has 
yet to reach the clinic. Nevertheless, a plethora of inhibitors targeting the 
downstream effectors of KRAS, such as Akt, MEK and BRAF, are currently being tested 
in clinical trials (www.clinicaltrials.gov). Furthermore, recent allosteric inhibitors 
against KRAS have been developed and showed promising results in vitro (47). 
However, it has been reported that differential KRAS mutations result in distinct MEK 
inhibitor responses, which demonstrates the complexity of targeting KRAS and its 
downstream effectors (48). Furthermore, targeting KRAS and its downstream 
pathways might establish acquired resistance as demonstrated in other cancer 
targets (49). Recent findings have shown that relapse occurs between 9 and 47 weeks 
after KRAS inactivation and tumour regression in genetic mouse models (50). KRAS 
re-activation was found in half of the population, while the other half demonstrated 
PDAC maintenance through YAP1, a protein in the hippo pathway which induces 
proliferation, invasion and epithelial mesenchymal transition (EMT) (50, 51). 
Moreover, several experiments have demonstrated the independency of K-Ras in 
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certain PDAC cell lines (52, 53). This demonstrates that multiple pathways might need 
to be targeted for effective treatment of PDAC. 
Other potential pathways for targeting include growth signalling pathways, such as 
epidermal growth factor (EGF), fibroblast growth factor (FGF), hepatocyte growth 
factor (HGF), insulin-like growth factor (IGF) and transforming growth factor-β (TGF-
β), and developmental signalling pathways, such as Hedgehog (Hh), Notch and Wnt. 
These pathways are known to be important in the development of the pancreas and 
have been reported to play a role in PDAC progression as well (54-56). However, 
more work is needed to improve these specific therapies, despite the lack of an 
favourable response in advanced and metastatic pancreatic cancer patients in clinical 




Figure 1-3. KRas downstream signalling pathways involved in cancer. 
KRas is normally activated through receptor tyrosine kinases (RTKs) signalling. In 
most cancers KRas is found in a constitutively active state and activate downstream 
signalling pathways. PI3K-Pdk1-Akt and Raf-Mek-Erk have been reported to be the 
major downstream pathways involved in PDAC progression (Illustration from 




 Pancreatic cancer subtypes 
The molecular and genetic alterations identified in genomic sequencing and 
translational studies has shown to contribute towards tumour heterogeneity in 
individual patients, resulting in the discovery of different sub-type classifications (37, 
53, 57-59). Subtype heterogeneity has been shown to be responsible for variability 
in therapeutic efficacy in breast and lung cancer (60, 61). In 2011, three subtypes for 
PDAC have been categorised through combinatorial analysis of transcriptional 
profiles of primary samples from various studies and combined with mouse and 
human cell lines: classical, quasi-mesenchymal (QM) and exocrine-like (53). The 
classical subtype is associated with high expression of adhesion and epithelial genes 
and KRAS dependency, while the QM subtype is associated with high expression of 
mesenchyme associated genes and low KRAS dependency. Furthermore, exocrine-
like subtype is associated with high expression of digestive enzyme genes. Each of 
these subtypes were correlated with difference in clinical outcome and therapeutic 
response (Figure 1-4).  
During the course of this project, additional subtypes have been described (37, 58). 
Waddell et al has established four subtypes with potential clinical utility based on 
structural variation patterns in chromosomal structure: Stable, Locally rearranged, 
Scattered and Unstable (58). In contrast, Bailey et al used RNA expression profiles to 
investigate the transcriptional networks and defined four subtypes that were similar 
to Collisson’s classification: Squamous (QM subtype), Pancreatic progenitor 
(Classical), immunogenic and aberrantly differentiated endocrine exocrine (ADEX) 
(Exocrine subtype) (37, 53). This finding further supports the presence of subtypes 





Figure 1-4. Survival of different subtypes. 
Survival curves of patients divided into the three different subtypes: Classical, quasi-
mesenchymal (QM-PDA) and exocrine-like. Different subtypes are linked with 





 Current therapies 
Current therapy for advanced pancreatic cancer is treatment with gemcitabine alone 
or in combination with other therapeutics (25). These combination chemotherapies, 
which include gemcitabine in combination with capecitabine or nab-paclitaxel, and 
the combi treatment of folinic acid (Leucovorin), 5-fluorouracil, irinotecan and 
oxaliplatin (FOLFIRINOX), have slightly improved the 1 year survival of advanced 
pancreatic cancer patients (Table 1-3) (62, 63).  
Gemcitabine is a deoxycytidine analog that is incorporated into DNA and inhibits DNA 
replication and repair through a ‘masked chain-termination’ process (64). Nab-
paclitaxel is an albumin-bound form of paclitaxel, and is found to inhibit cell division 
through blocking the depolymerisation of microtubules (65). Capecetabine is a 
fluoropyrimidine and is metabolised into 5-fluorouracil (5-FU) in 3 steps (66). 5-FU is 
an uracil analogue with a fluorine atom at the C-5 position instead of hydrogen and 
blocks DNA replication through inhibiting thymidylate synthase and by incorporating 
itself into DNA (67). Folinic acid has been shown to enhance the effects of 5-FU on 
thymidylate synthase (68). Irinotecan inhibits DNA topoisomerase I and oxaliplatin is 
a platinum based DNA damaging drug (67). However, none of the therapies are 
targeting specific pathways in pancreatic cancer, and display severe side effects with 
modest benefits. 
Several attempts in targeting pathways have been successful in genetic mouse 
models in vivo, but has been translated into minimal efficacy in clinical trials. For 
example, Erlotinib, a small molecule inhibitor targeting the EGFR tyrosine kinase is 
the only approved targeted therapeutic used in combination with Gemcitabine. 
Nevertheless, the survival benefit only increased from 5.9 months to 6.2 months on 
average (69). Similarly, Cetuximab, an antibody against EGFR have been tested in 
clinical trials with little efficacy (69, 70). Other notable examples include combination 
therapy of gemcitabine with the IGFR antibody (Ganitumab), VEGF antibody 
(Bevacizumab) or the Smoothened (SMO) inhibitor Saridegib, all of which failed to 
demonstrate improved survival compared to gemcitabine alone (71-73). These 
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studies demonstrate the molecular complexity of PDAC and differences between 
therapeutic successes in genetic mouse models and clinical trials. However, majority 
of the clinical studies are conducted in advanced or metastatic pancreatic cancer 
patients and could potentially provide improved response and outcome in non-
metastatic or resectable pancreatic cancer patients. Nevertheless, novel therapies 
targeting pancreatic cancer invasion mechanisms could benefit resectable and 
unresectable patients. 
Recent advances in immunotherapy in other cancers such as melanoma and lung 
have prompted promising outcomes for pancreatic cancer patients. However, 
immunotherapy has not been successful in treating advanced pancreatic cancer thus 
far. A phase I study demonstrated that none of the 14 patients with locally advanced 
or metastatic pancreatic cancer patients responded to the treatment with a 
programmed death-ligand 1 (PD-L1) specific monoclonal antibody (74). In a phase II 
study, only one out of 27 locally advanced or metastatic pancreatic cancer patients 
responded to the treatment with Ipilimumab, an anti-CTLA-4 monoclonal antibody, 
in a significant delayed response (75). Nevertheless, these studies did not screen 
patients on microsatellite instability in their tumours, which has been associated with 
an increased rate of response to immunotherapy, especially in melanoma and lung 
cancer patients (76, 77). This suggests that immunotherapy in pancreatic cancer 
might not be as promising and needs further investigation. Furthermore, this also 
highlights the need for alternative therapies against pancreatic cancer. 
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Table 1-3. Therapies for pancreatic cancer and their 1-year overall survival rates. 
Drug combination 1-year overall survival 
Gemcitabine 20.6-22% (62, 63) 
FOLFIRINOX 48.4% (62) 
Nab-Paclitaxel-Gemcitabine 35% (63) 




1.2. The role of the tumour microenvironment in PDAC 
The tumour microenvironment plays a crucial role in the progression of pancreatic 
cancer and could influence the outcome of therapeutics. The majority of the 
pancreatic tumour volume is made up by the tumour stroma (79). Furthermore, 
stromal cells and immune cells are known to have an important role in PDAC 
progression and therapeutic resistance (80, 81). Therefore, the key to therapeutic 
success may lie in understanding the interplay of various compartments in the 
tumour microenvironment and the tumour.  
Desmoplasia, the proliferation of fibrotic tissue, is one of the hallmarks of PDAC and 
is characterised by a large tumour stroma that undergoes extensive remodelling with 
increased expression of collagen I and the loss of normal tissue architecture. Cross-
talk between normal epithelial cells, invading tumour cells, fibroblasts, pancreatic 
stellate cells (PSC), endothelial cells, and infiltrated inflammatory cells, which are all 
embedded within the extracellular matrix (ECM), are found within the tumour 
stroma (80, 82) (Figure 1-5). The complex interplay within the stroma results in 
autocrine and paracrine signalling activated through secreted growth factors that 
sustain the tumour and promotes tumour growth and metastasis (82, 83). 
Furthermore, unlike the majority of tumours, there is a poor angiogenic response in 
PDAC. The desmoplastic reaction results in an abnormal vasculature with leaky blood 
vessels and capillaries that induces a hypoxic environment (79).  
Researchers have tried to target the tumour microenvironment for PDAC therapy, 
but its increased ECM stiffness, induced hyaluronic acid (HA) content, high interstitial 
fluid pressure (IFP) and hypovascular nature lead to decreased delivery and efficacy 
of chemotherapy (84, 85). Therefore, it was thought that stromal depletion could 
enhance therapeutic response. However, recent reports on the depletion of PSC in 
the microenvironment demonstrated increased tumour progression and 
aggressiveness (86, 87). Alternatively, another study has demonstrated that targeting 
lysyl oxidase (LOX) in KPC mice can inhibit metastasis and increase the efficacy of 
Gemcitabine through reducing collagen cross-linking in the stroma (88). Additionally, 
the use of PEGPH20, a drug that degrades Hyaluronan in the tumour 
microenvironment of pancreatic cancer patients has demonstrated increase efficacy 
 38 
when used in combination with nab-paclitaxel plus Gemcitabine versus nab-
paclitaxel plus gemcitabine alone in a phase II trial (89). These studies have shown 
that the role of the tumour microenvironment increases the complexity of PDAC 
therapy, yet yield a large potential as therapeutic target. Future experiments should 
include stromal cells from the tumour microenvironment in order to discover 






Figure 1-5. A schematic representation of complex cross-talk interactions between 
various components in the tumour microenvironment of PDAC. 
Immunosuppressive cells (tumour associated macrophages (TAM), regulatory T cells 
(Tregs) and myeloid derived suppressor cells (MDSCs)) infiltrate the stroma and 
induces pro tumorigenic inflammation. Tumour epithelial cells (TEC) activates PSCs 
in the mesenchymal compartment induces production of ECM components and 
subsequently invasiveness in TECs. PSCs are in turn able to sustain their own activity 
through autocrine signalling. The ECM undergo extensive remodelling and induces 
HA production, IFP and stiffness, contributing to resistance to chemotherapy. 
(Illustration adapted from Stromnes et al 2014) (80). 
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 Pancreatic stellate cells 
Pancreatic stellate cells are star-shaped fibroblasts found in the periacinar space and 
comprises 4% of the organ in their dormant state (90). They are characterised by 
abundant lipid droplets in the cytoplasm and have low capability of ECM synthesis 
and low cell division activity (79). Furthermore, PSCs express glial fibrillary acid 
protein (GFAP), nestin, vimentin, desmin, N-cadherin and nerve growth factor (NGF), 
which distinguishes them from other fibroblasts (91).  
Secreted cytokines (IL-1 and IL-6) and growth factors (FGF, PDGF, TGF-β and VEGF) 
by inflammatory cells and pancreatic cancer cells (PCCs) are able to activate PSCs (90, 
92). Upon activation, PSCs will lose their lipid content and adopt a myofibroblastic 
phenotype characterised by the expression of α-smooth muscle actin (α-SMA) (93). 
Activated PSCs are already found in PanIN stages and are the major contributor of 
ECM proteins with collagens I, III and fibronectin being the major components of the 
fibrotic tissue (93). Through secretion of ECM proteins, growth factors ((FGF, PDGF, 
TGF-β1 and VEGF), inflammatory cytokines and chemokines (CXCL12 and IL-6), and 
proteases such as matrix metalloproteinases (MMPs), PSCs are capable of sustaining 
PSC activation through autocrine and paracrine signalling, as well modulating the 
matrix and inducing PDAC progression (80, 90, 92, 94). Co-culture of PCCs and PSCs 
induced proliferation of PCCs through Notch signalling in vitro (95). Furthermore, 
PSCs enhanced sphere formation abilities of pancreatic cancer cells and induced 
resistance to radiation therapy and Gemcitabine, implicating increased ‘stemness’ 
(characteristics of stem cells; self-renewal and pluripotency) and a cancer stem cell 
population in PDAC with increased drug resistance (96-98). Moreover, combined 
orthotopic injection of PSCs and PCCs in nude mice demonstrated increased tumour 
growth, desmoplasia and metastasis compared to injection of PCCs alone (99, 100).  
However, studies have also reported that PSCs also act as a restrictor of tumour 
progression (86, 87, 101). Indeed, a recent study has demonstrated that PSCs 
differentiate into two types of cancer associated fibroblasts (CAFs) (102). The 
researchers shown that by using a novel three-dimensional co-culture platform, they 
were able to recapitulate in vivo CAF heterogeneity by demonstrating ECM 
deposition by activation of PSCs and promoted proliferation of pancreatic organoids. 
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Through characterising the organoid and PSC co-culture, the authors have identified 
a population of CAFs in close proximity to the epithelial organoids expressing strong 
αSMA, named myofibroblastic CAFs (myCAFs) (102). Another population of CAFs with 
high expression of IL-6 and low αSMA expression was found to be more distantly 
distributed from the epithelial cells away. These CAFs are termed inflammatory CAFs 
(iCAFs), and increase inflammatory cytokines through paracrine signalling (102). This 
study suggests that myCAFs could have anti-tumorigenic activity and was removed in 
the CAF depleting experiment selected on αSMA expression, whereas the iCAFs have 
pro-tumorigenic activity and were not removed in the mouse models, resulting in 
increased progression of the cancer (86). However, it must be noted that both iCAFs 
and myCAFs are mutually exclusive but reversible subtypes (Figure 1-6). Therefore, 
further elucidating the pro- and anti- tumorigenic impact of PSCs is crucial for 
therapeutic development against PDAC.  
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Figure 1-6. Schematic of relation between PSCs, myCAFs and iCAFs.  
Upon activation, quiescent PSCs can differentiate either into myofibroblastic CAFs 
(myCAFs) through juxtacrine interactions or into inflammatory CAFs (iCAFs) through 






1.3. Cancer metastasis 
Tumour metastasis is known to be the main cause of cancer lethality (103, 104). 
Tumours metastasise by cancer cell dissemination, migration and invasion into 
surrounding stroma. Afterwards, cancer cells intravasate into the bloodstream and 
survive the sheer force and pressure, and then extravasate from the bloodstream to 
a distant site and colonize into a new metastatic lesion (105). The high propensity of 
PDAC dissemination has led to a poor survival rate of patients, where often 
metastasis has already occurred by the time of diagnosis or has been undetectable 
in the form of micro-metastases (25). In order to treat PDAC metastasis, it is 
important to understand the underlying morphological and molecular mechanisms. 
Several studies have already reported the regulation of pancreatic cancer migration 
and invasion.  
 Regulation of cellular morphology during migration and invasion 
Cells are able to interconvert between various modes of cellular migration to 
facilitate cell migration and invasion through various barriers. Individual cell 
migration and invasion can be highly plastic, allowing cells to switch between an 
elongated/mesenchymal-like and a rounded/amoeboid-like mode of movement to 
effectively migrate and invade through various tissue types (105). ROCK1 and ROCK2 
are serine/threonine protein kinases of the AGC kinase family and can be activated 
by active Rho to interact with kinases such as LIM domain kinase 1 (LIMK1) and 
myosin-light chain2 (MLC2), which are involved in the regulation of the cytoskeleton 
(106, 107). Recently, it has been shown that novel AKT inhibitors (AT13148 and 
CCT129245) were able to inhibit ROCK signalling and subsequently actomyosin 
contractility, causing impaired cellular invasion of both amoeboid and mesenchymal 
cells in melanoma (108). Actomyosin contractility is regulated by ROCK signalling and 
is necessary for maintaining cellular shape in all types of cells, but different levels 
determine different modes of migration (108). Activation of ROCK signalling leads to 
increased actomyosin contractility at the cortex through mono-phosphorylation of 
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MLC2 at Serine 19 (109). It has also been reported that components of the STRIPAK 
complex, which regulate actomyosin contractility through inhibiting 
dephosphorylation of pMLC2, are involved in the regulation of the mode of cellular 
migration and metastasis (110). Amoeboid cells have increased activation of the Rho-
ROCK signalling pathway (111) together with activation of JAK1 signalling (112), 
whereas the mesenchymal mode of migration is characterised by an elongated 
morphology with actin rich protrusions through increased Rac1 GTPase activation 
(113). The increase in actomyosin contractility at the cortex allows amoeboid cells to 
migrate through formation of blebs, which are protrusive structures capable of 
directing migration (114). A study from the Sanz-Moreno lab has shown that MMPs 
are able to regulate amoeboid cancer cell migration (115). Therefore, it might be 
possible that MMPs secreted by PSCs induce amoeboid phenotypic migration and 
invasion in PDAC. Nevertheless, various studies have demonstrated that PSCs induce 
invasion through EMT in PDAC (97, 116, 117).  
Other studies have demonstrated that mutant p53 driven spatiotemporal regulation 
of RhoA activity was associated with increased invasiveness of pancreatic cancer cell 
(118, 119). This was further supported by another study, which demonstrated that 
the increase in cAMP levels decreased the levels of active RhoA or RhoC and leads to 
the inhibition of PDAC cell motility through F-actin remodelling (120). Furthermore, 
focal adhesion kinase and Src has been shown in other cancers to regulates E-
cadherin dependent collective cell movement in a complex three-dimensional 
tumour environment (121). Moreover, Src inhibitor Dasatinib has demonstrated 
inhibition of metastasis in pancreatic cancer mouse model (122). These findings 
suggest that the role of actomyosin contractility and actin remodelling should be 
further investigated to increase or understanding of cellular plasticity and motility in 
pancreatic cancer. 
  Epithelial-mesenchymal transition 
EMT is a process of cellular plasticity and induces a phenotypic change from a round-
epithelial to an elongated-mesenchymal phenotype during embryonic development, 
tissue regeneration and wound healing (123). EMT has also been shown to promote 
migration, invasion, cancer stemness, as well as resistance to therapy in pancreatic 
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cancer (124-126). PSC cells are known to secrete extra cellular factors such as TGF-β, 
FGF, PDGF, EGF, MMP-2, MMP-9, collagen type I and III, and hyaluronic acid to induce 
EMT in pancreatic cancer cells through the activation of transcription factors Zeb1, 
Slug, Snail and Twist (127). These transcription factors suppresses genes regulating 
the epithelial phenotype (126). This leads to the down-regulation of the epithelial 
marker E-cadherin, nuclear translocation of β-catenin, and the up-regulation of 
mesenchymal markers such as N-cadherin, vimentin and fibronectin in the pancreatic 
cancer cells. It has been reported that up-regulation of N-cadherin and vimentin in 
primary tumours of PDAC patients were correlated to increased invasion and 
metastasis (128). Furthermore, zeb1 induced EMT was shown to induce resistance to 
gemcitabine in pancreatic cancer cell lines (124). Moreover, depletion of Zeb1 
blocked EMT and invasion in an in vivo mouse model (129). In addition, another study 
has shown that inflammation induce EMT and accelerate metastasis in an in vivo 
mouse model during early stages of pancreatic cancer progression (130). Also, EMT 
transcription factor Slug has been demonstrated to regulate actin bundling protein 
fascin during late stage PanIN and PDAC formation in a mouse model for pancreatic 
cancer. Fascin was able to promote the formation of filopodia and increase invasion 
in PDAC cells (131). Thus, EMT plays an important role in PDAC invasion and 
metastasis.  
 
 Collective cell migration 
Cancer cells are able to invade individually or in a collective manner. 
Histopathological sections often demonstrate collective cell invasion in tumours, 
which are able to move in organised structures such as cell strands and luminal 
structures like acini and glands (132). Cells that migrate and invade collectively 
remain cohesive while moving, mainly due to the retained expression of cell-cell 
junction proteins (133). These cell-cell junction proteins include tight junction 
proteins, gap junctions, catenins and cadherins, which play an important role in 
mediating front-rear polarity, cytoskeletal synchronisation and mechanocoupling 
during migration (134-136). It has been suggested that MLC2 activity might have a 
role in guiding collective cell migration rather than driving the migration, through 
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modulating cell shape and cortical actomyosin dynamics (137, 138). Recently, it has 
also been suggested that actomyosin contractility might be important in the 
retrograde flow of N-cadherin based junctions from the cell front to the rear and 
recycled back to the front to induce movement similar to a ‘treadmill’ (139). In 
addition, another study has shown that RhoA regulates the interaction between the 
leading cell and the following cells, inducing a hierarchy and increased multicellular 
cytoskeletal contractility (140). These studies demonstrate the important role of 
actomyosin contractility in guiding collective cell migration and invasion. Although 
collective cell invasion has not been extensively investigated in PDAC, it has been 
shown recently in PDAC organotypics (141). It is important to identify collective cell 
structures with differences in actomyosin contractility, and distinguish single cell and 




The limitation of effective therapies against pancreatic cancer and pancreatic cancer 
invasion calls for the discovery and the development of novel therapies. Current 
available pancreatic cancer models that accounts for factors in the tumour 
microenvironment, such as the organotypic assay or in vivo genetic engineered 
mouse models, are expensive and not suitable for drug screening purposes. It was 
therefore hypothesised that by developing and performing a drug screen in a 3D 
pancreatic cancer invasion model in vitro would yield promising hits against the 
progression of invasive pancreatic cancer. 
As mentioned previously, pancreatic cancer behaviour and mode of migration has 
previously not been investigated. Therefore, the first aim of this study is to 
investigate and characterise the cellular morphology and plasticity in pancreatic 
cancer across a panel of human PDAC cell lines. The characterisation will provide the 
basis for the selection of a robust, highly invasive cell line model for the drug screen 
platform.  
In order to bridge 2D plastic culture and in vivo or clinical models, the second aim of 
this study is to develop a 3D in vitro model with the selected cell line model and 
tumour microenvironment factors to investigate pancreatic cancer invasion. 
Furthermore, the model will be designed and optimised for drug screening against 
pancreatic cancer invasion.  
In the final part of this work, the aim is to identify potential novel therapeutics by 
performing a drug repurposing screen with the developed 3D drug screen platform 
against pancreatic cancer invasion. A drug library with selected FDA approved drug 





 Methods and materials 
2.1. Cell culture 
Pancreatic ductal adenocarcinoma cell lines (Table 1) Capan1 (Kindly provided by Prof. 
H. Kocher at Barts Cancer Institute, UK), Capan2, PaTu8902 (Obtained from DSMZ, 
Germany), Colo-357 (Kindly provided by Prof. Michalski University Hospital 
Heidelberg, Germany) and SW1990 (Kindly provided by Dr. G. Sala at University of 
Chiety-Pescara, Italy) were cultured in RPMI (Sigma) supplemented with 10% fetal 
bovine serum (FBS) (Gibco) and 1mM Penicillin/streptomycin (Gbico). Panc-1 (Kindly 
provided by Mr. H. Kocher at Barts cancer institute, UK), PaTu8988T, PaTu8988S 
(Kindly provided by Dr. F. U. Weiss at Ernst Moritz Arndt Universitat Greifswald, 
Germany), Suit2-007 and Suit2-028 (Kindly provided by Dr. L. Castellano, Imperial 
College London, UK) were cultured in DMEM (Sigma) supplemented with 10% FBS 
and 1mM Penicillin/streptomycin. HPAC (Kindly provided by Dr. J. Hernandez Losa at 
Hospital Universitario Vall d’Hebron Barcelona, Spain) was cultured in DMEM/F12 
(Sigma) supplemented with 10% FBS and 1mM Penicillin/streptomycin. CFPAC-1 
(Kindly provided by Dr. A. Pessina at Universita degli studi di Milano, Italy) was 
cultured in IMDM supplemented with 10% FBS, 1mM penicillin/streptomycin. 
Pancreatic stellate cell line PS-1 (Kindly provided by Mr. H. Kocher at Barts cancer 
institute, UK) was maintained in DMEM/F12 supplemented with 10% FBS, 1mM 
Penicillin/streptomycin and 1ug/ml Puromycin (Sigma) as selection marker(142). All 
cell lines were cultured at 37°C under 5% CO2 with regular medium replacement. All 
cell lines were regularly tested mycoplasma negative by DAPI staining or by using the 
Sigma Lookout mycoplasma PCR detection kit (MP0035) when cultured in the 
absence of penicillin/streptomycin for at least 4 days. 
Cells were grown as attached monolayers in sterile culture flasks (T75 from TPP or 
T25 and T175 from Nunc) up to a confluency of ~80% prior to washing with sterile 
PBS-/- (Gibco) and were enzymatically detached with 0.5% Trypsin-EDTA (Gibco) by 
incubation at 37C under 5% CO2 between 3 to 10 min. Growth medium was added to 
inactivate the trypsin and the cell suspension was transferred into a falcon tube for 
centrifugation at 200g for 5min at RT. The supernatant was then removed and cells 
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were resuspended with fresh growth medium into single cells for further passaging 
or seeding for an experiment. 
Lentiviral vectors containing Lifeact-GFP and Lifeact-Mrfpruby were kindly gifted by 
Prof. M Parsons at King’s College London. Stable expressing Patu8988T Lifeact-GFP, 
PaTu8902 Lifeact-GFP and PS-1 Lifeact-Mrfpruby were generated as previously(143). 
Briefly: Lifeact lentiviral, packaging and envelope vectors were transfected into HEK 
293T cells with lipofectamine 3000 (Invitrogen). Viral particles were harvested by 
collecting and passing the supernatant through a 0.45μM filter (Millipore) before 
infecting target cells. Infected cells were passaged 5 times to clear out all the viral 
particles and were then FACS sorted for medium and high level GFP/Mrfpruby 
expression with a BD FACSARIA 3 Fusion in a sterile hood by the staff at the Guy’s St. 
Thomas NHS Trust BRC flowcore. 
 
2.2. Morphological characterisation on 2.5D Collagen 
Morphological characterization on 2.5D collagen was conducted on a thick layer of 
type 1 Collagen described as previously (115). A collagen mixture containing a final 
concentration of 1.7mg/ml PureCol bovine collagen type I (Advanced Biomatrix) in 
DMEM (GIBCO) was added into a 24-wells plate (300ul per well) and left polymerizing 
for 2 hours at 37°C with 5% CO2. Similarly, 100ul per well of collagen mixture was 
added in a 96-wells for immunofluorescence staining purposes.  2-4x104 cells were 
then seeded in triplicate onto the thick layer of collagen in growth medium, allowed 
to adhere for 20 hours at 37°C with 5% CO2. Thereafter, medium was aspirated 20 
hours post seeding and cells were then washed twice with PBS (Ca2+/Mg+) (Gibco) 
prior to culturing in 1% FBS containing medium to prevent cell division, as cell division 
increases the tendency of cells to become roundly shaped. For morphological 
analysis, two to three phase contrast images were taken of each cell line in a 24-wells 
plate per individual experiment with a Qicam (Qimaging) attached to a Nikon TS100 
inverted microscope with a x10 objective at 24 and 48 hours post seeding.  
Additionally, for time-lapse microscopy, 20mM HEPES was added to each well 24hrs 
post seeding.  The plate was then wrapped with parafilm and put on a heated stage 
 50 
at 37C of an Olympus IX 71 with Qicam (Qimaging) and QCapture pro software 
(Qimaging). The cells were recorded for 16hrs overnight. 
Morphological events were analyzed by counting the number of single cell events 
(Individual cells, not connected to any other cells), doublet cell events (cells 
undergoing division or two cells connected to each other), clustered cell events 
(group of cells (more than 2 cells) found attached to each other, which might form 
colonies) and colony cell events (group of cells (more than 2 cells) found in a tightly 
packed colony with defined borders) in ImageJ (Figure 1a). The total number of 
morphological events (100%) is defined as the sum of all events per field. Single cell 
morphology was defined by the ‘roundness’ of single cells, which was determined by 
manually drawing around the border of individual cells and measuring the ‘roundness’ 
shape descriptor in ImageJ. Cells with a roundness index of closer to 1 were seen as 
amoeboid and closer to 0 were seen as mesenchymal phenotype.  
 
2.3. Immunofluorescence 
Assessment of E-cadherin and pMLC (S19) expression was carried out in cells on thick 
layer collagen type 1. 1-2x104 cells cultured on thick layer collagen in 96 wells plate 
were fixed for 15min at room temperature with a final concentration of 4% 
paraformaldehyde 48 hours post seeding. Cells were then rinsed twice with PBS 
(Ca2+/Mg+) prior to permeabilisation with 0.3% triton-x100 in blocking buffer (4% 
Bovine albumin serum (BSA) (VWR) in PBS (Ca2+/Mg+)) for 20min at room 
temperature. Thereafter, cells were rinsed and incubated with blocking buffer for 
30min at room temperature. Cells were afterwards incubated with primary antibody 
(Mouse anti-E-cadherin (Abcam; HECD-1) with a final dilution of 1:100 or Rabbit anti-
p-MLC2 (S19) (Cell signaling; #3671) in a final volume of 30ul blocking buffer per well 
on top of the 100ul thick layer collagen overnight at 4°C. The next day, after five 
rinses with PBS (Ca2+/Mg+), cells were incubated with secondary antibody (Goat anti-
Mouse- or Goat anti-Rat- Alexa Fluor 488nm conjugated with a final dilution of 1:500), 
Phalloidin-Rhodamine (Invitrogen) with a final dilution of 1:300 and DAPI (Sigma) 
with a final dilution of 1:10000 in a total volume of 50ul blocking buffer per well on 
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top of 100ul thick layer collagen protected from light for 2 hours at room 
temperature. Afterwards, cells were rinsed six time with PBS (Ca2+/Mg+) and stored 
in PBS (Ca2+/Mg+) protected from light at 4°C till image acquisition. Imaging was 
carried out by transferring the collagen gel upside down onto a glass-bottomed dish 
(MatTek) and confocal images were taken with the Zen software on a Zeiss LSM 510 
Meta (Carl Zeiss) confocal microscopy with a C-apochromat x40/1.2 NA water based 
objective.  
Dewaxed organotypic specimen sections were marked around with a deliminating 
wax pen (DAKO) prior to permeabilisation with 0.2% Triton X-100 in PBS for 5min at 
room temperature. Sections were washed twice with PBS prior to auto fluorescence 
quenching by incubation with freshly prepared quenching buffer (1mg/ml sodium 
borohydride (Sigma) in PBS) for 10 minutes at room temperature. Samples were then 
washed again with PBS prior to blocking with blocking buffer (5% BSA in PBS) for 
30min at room temperature. Thereafter, samples were incubated with primary 
antibody (Rabbit anti-cytokeratin for widespectrum screening (DAKO; Z062201-2) 
with a dilution of 1:500 or Mouse anti-αSMA (Dako; clone 1A4) with a dilution of 
1:300) in blocking buffer overnight at 4°C. The next day, samples were washed with 
PBS and then incubated with secondary antibody (Goat anti-Mouse-Alexa Fluor 
546nm conjugated and Goat anti-Rabbit-Alexa Fluor 488nm conjugated with a final 
dilution of 1:200 in blocking buffer protected from light for 1 hour at room 
temperature. Unbound secondary antibodies were washed with PBS and samples 
were incubated with DAPI (1:10000 dilution in PBS) protected from light for 5min at 
room temperature. Samples were washed three times with PBS prior to washing in 
dH2O at room temperature. A coverslip was mounted onto the samples with 
Fluorsave mounting medium (Calbiochem). Images were taken on an Olympus 
IX71inverted fluorescence microscope with Qicam (Qimaging) and QCapture pro 
software (Qimaging).  
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2.4. Dewaxing paraffin embedded sections 
Paraffin embedded sections of organotypics were rehydrated as following: 2x 5min 
in Xylene, 2x 3min in 100% EtOH (VWR), 3min in 80% EtOH, 3min in 70% EtOH, 3min 
in 50% EtOH, rinse in dH2O and afterwards in PBS. Heat assisted antigen retrieval was 
carried out with slides immersed in 10mM Na+ - Citrate buffer (adjusted to pH 6 with 
Citric acid) and boiled for 20 min in the microwave. Water was topped up ensuring 
stable concentration and equal volume during boiling. Samples were left to cool 
down to room temperature prior to three x 1min rinses in PBS.  
2.5. Spheroid formation and 3D spheroid invasion assay 
Spheroids were prepared in Corning black walled 96-wells clear black round bottom 
ultra-low attachment spheroid microplates (Cat nr 4515). 1*103 cancer cells were 
seeded in 200ul DMEM-F12 growth medium per well, to generate a single spheroid 
per well. Alternatively, 500 cancer cells and 500 PS-1 cells were mixed and seeded in 
200ul DMEM/F12 growth medium per well to yield co-culture spheroids. The plate 
was then centrifuged at 200g for 8min at room temperature to facilitate cell spheroid 
formation. Cells were cultured at 37°C with 5% CO2 for three days prior to invasion 
assay initiation. Images were taken with an 10x objective on an Olympus 
IX71inverted fluorescence microscope with Qicam (Qimaging) and QCapture pro 
software (Qimaging).  
When spheroids are assembled on day three, 170ul medium was removed by 
multichannel pipetting. A collagen mixture was prepared on ice consisting of 2.0 
mg/ml Corning rat tail collagen I, 1x DMEM, 10% FBS, collagen volume x 0.023 ul of 
1N NaOH and topped up with sterile distilled water to the total volume. 100ul 
Collagen matrix was then added to each well with a multichannel pipette. Spheroids 
should stay at the centre bottom of the well for the best result and reproducibility. 
The plates were then left polymerizing at 37°C with 5% CO2 for 2 hours. 100ul DMEM-
F12 supplemented with 10% FBS and 1mM Penicillin/streptomycin was then added 
on top to initiate the assay. For the drug screen, DMSO (Negative control for invasion 
inhibition), Dasatinib (Positive control for invasion inhibition) or test compound could 
be added to the medium on top to initiate the assay. Phase contrast images were 
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taken with a Qicam (Qimaging) attached to a Nikon TS100 inverted microscope with 
x4x objective at 0hrs (Start) and at 96 hrs (End). Alternatively, images can be taken 
at 24, 48 and 72hrs for additional tracking of the spheroid invasion and growth. 
2.6. Image analysis and image quantification of spheroid invasion 
GFP and phase contrast images were taken of each well containing a single spheroid 
at the beginning of invasion (day 0) and at the end of invasion (day 4). The phase 
contrast and GFP fluorescence images were transformed to 8bit in ImageJ. The 
brightness and contrast of the GFP fluorescence was then adjusted for each image to 
overlay and capture the size of the spheroid and the invasive cells. Afterwards, the 
thresholding was applied and set to quantify the area of the GFP signal. The area of 
the spheroid body and invaded cells at the end of the invasion data was then 
normalised against the area of the spheroid at the start of the invasion to yield the 
relative invasion result. Statistical analysis was done by using the average of the 
triplicate results from each experiment and compared across three independent 
experiments with one way ANOVA in the case of multiple drug conditions.  
2.7. Mini 3D organotypic assay 
24-wells 6.5mm diameter transwells with 0.4µm pore size (Corning; #3413) were pre-
coated with 300ul 40µg/ml rat tail collagen type I (Corning) for 1 hour at 37°C with 
5% CO2. A collagen/matrigel mixture was prepared at 2.0mg/ml Rat tail collagen type 
I with 1.5mg/ml Matrigel with reduced growth factor (Corning) in DMEM 
supplemented with 10% FBS on ice. Excess collagen was then removed and 120ul of 
the collagen/matrigel mixture was added per transwell and polymerized at 37°C with 
5% CO2 for 2 hours. A total amount of 1x106 cells either consisting of cancer cells 
alone, pancreatic stellate cells alone or a mix of cancer cells and pancreatic stellate 
cells in a 1:2 ratio, were seeded in DMEM/F12 supplemented with 10% FBS and 1mM 
penicillin/streptomycin on top of the transwell. The bottom of the wells was filled 
with 650ul DMEM/F12 supplemented with 10% FBS and 1mM 
penicillin/streptomycin. Cells were left to attach overnight at 37°C with 5% CO2. The 
next day, medium on the top was changed to serum free DMEM/F12 supplemented 
with 1mM penicillin/streptomycin and the bottom medium was replaced with 350ul 
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complete DMEM/F12 medium. Medium was changed every other day for 7 days. 
Transwells were then fixed with 200ul and 600ul of 10% universal formalin (Sigma) 
for top and bottom respectively overnight at room temperature. Transwells were 
then rinsed in 70% EtOH for 10min at room temperature prior to membrane cutting 
and gel removal, wrapped in specimen sponges into a specimen case for automated 
processing, paraffin embedding, sectioning (Section thickness: 5µm), and 
hematoxylin and eosin (H&E) staining at Barts cancer institute, London, UK. 
 
2.8. Immunoblotting 
Cells were seeded in 6-well plates and maintained as outlined above for 24 hours. 
Lysates were generated of 70% confluent wells by washing the cells with PBS and 
lysis with 100ul NP40 based lysis buffer/well (0.5% NP-40, 30mM sodium 
pyrophosphate, 50mM Tris-HCl pH 7.6, 150mM NaCl, 0.1mM EDTA, 50mM NaF, 1mM 
Na3VO4, 1mM PMSF, 10µg/ml leupeptin and 1µg/ml aprotinin and 1mM DTT (all 
Sigma)) on ice for 10min. Lysates were then scrapped, transferred to an Eppendorf 
tube and centrifuged at 13 000 x g for 15min at 4°C. Supernatant was then 
transferred to new Eppendorf tube and boiled for 3 min at 95°C in 6x laemmli buffer 
(Final concentration: 1x, 375mM Tris-HCl pH 6.8, 6% SDS, 48% Glycerol, 9% β-
mercaptoethanol and 0.03% bromophenol blue (all Sigma)). Samples were stored at 
-20°C.  
30ul of protein samples were resolved by SDS/PAGE on 6.5% gels (1.25ml 3M TRIS, 
2.17ml 30% acrylamide, 100µl SDS, 6.48ml ddH2O, 100µl ammonium persulphate, 
10µl TEMED) and transferred onto nitrocellulose membrane by wet transfer for 1 
hour at 100V on ice. Membranes were blocked with 5% skimmed milk powder 
(Marvel) or 5% BSA in TBST (1M TRIS pH 7.6, 5M NaCl, 1% Tween 20) for 30min at 
room temperature. Primary antibodies (Mouse anti-E-cadherin (Abcam HECD-1) with 
dilution of 1:1000, Mouse-anti-N-cadherin (BD transduction laboratories; #32) with 
dilution of 1:1000, Mouse anti-Vimentin (Abcam ab20346) with a dilution of 1:1000, 
Rabbit anti-pMLC2(T18/S19) (Cell signaling #3674) with a dilution 1:1000, Mouse 
anti-MLC2 (Santa Cruz SC 15370) with a dilution of 1:200 or Mouse anti-GAPDH 
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(Santa Cruz; SC32233) with a dilution of 1:40000) in blocking buffer were incubated 
overnight at 4°C on roller bench. Membranes were then washed three times with 
TBST and incubated with secondary antibodies (Goat-anti-Mouse-HRP conjugated or 
Goat-anti-Rabbit-HRP conjugated (both DAKO) with final dilution of 1:2000) in 
blocking buffer for 1 hour at room temperature. Afterwards, membranes were 
washed three times again with TBST and developed with ECL chemo luminescence 
kit (Thermo Scientific) and Fuji Medical X-ray Film (Fuji Film). Densitometry analysis 
of specific bands was carried out with ImageJ. Target protein expression levels were 
compared over the loading control (internal housekeeper protein) on the same 
membrane. 
 
2.9. Viability assay on 2.5D collagen I matrix 
Cells were seeded on 2.5D collagen I matrix prepared as described above and allowed 
to adhere for 20 hours at 37°C with 5% CO2. Next day, cells were treated with 
different concentrations of drug compound and DMSO as negative control in growth 
medium. After 72hrs, alamar blue (Acros organics) is added to the medium, yielding 
final concentration of 44uM and left incubating for 2 hours at 37°C with 5% CO2. 
Fluorescence signal of was then read with a Perkin Elmer Fusion Alpha-FP microplate 
reader.  
 
2.10. Tumour xenografts and intravital in vivo imaging 
1 x 106 PaTu8902 cells stably expressing Lifeact-GFP were suspended in 100 μl of 
PBS:Matrigel (50:50) and injected  subcutaneously into the flank of 6- to 8-week CD-
1 nude mice (n=3). Tumour growth was monitored and when tumours reached visible 
size (5–8 mm in diameter), mice were anesthetized and imaged as described (144). 
For intravital imaging, seven to ten different regions were imaged simultaneously for 
two hours for each tumour (approximately 50 µm deep on average). Mice were kept 
in accordance with UK regulations under project PPL80/2368. 
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2.11. Genetic analysis 
Gene enrichment analysis was performed using GSEA 
(http://www.broadinstitute.org/gsea/index.jsp). Each gene in the gene set is 
represented in the x-axis, while the enrichment score for each gene is plotted in the 
y-axis. GSEA analysis does not apply a threshold to the data. 
 
2.12. Statistical analysis 
Statistical analysis was carried out on the averages of 3 or more independent 
experiments (n=3), using Graphpad Prism software. Student’s T-test, ANOVA or Two-
way ANOVA were used for parametric data when two groups, multiple groups or 
multiple groups with two independent factors were compared respectively. Tukey’s 
multiple comparisons test was applied where applicable. Kruskis-Wallis test was 
applied for non parametric data with multiple comparisons. P value of less than 0.5 
was deemed significant. Pearson correlation coefficient statistical analysis was 
performed for the comparison of data on linear relationship, with a positive p value 
deemed as having a linear correlation. 
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 Morphological Characterisation and Cell Line Model 
Identification for the Drug Screen 
3.1. Introduction 
Early cancer cell dissemination and poor response to current available treatments 
highlight the need for novel therapeutics and targets for tackling PDAC. The majority 
of cancer therapies are cytostatic drugs or traditional chemotherapy, initially 
designed to target cell proliferation in hematopoietic cancers with high proliferation 
capabilities, such as Gemcitabine which is the standard of care for PDAC. 
Nevertheless, metastasis is the leading cause of cancer death by solid tumours such 
as PDAC. Around 60% of PDAC patients are presented with local invasion whereas 
around 30% are diagnosed with distant metastasis (145). Therefore, more focus is 
needed in developing novel therapies against invasion and treating metastatic 
disease. 
Cellular migration and invasion underlie the metastatic dissemination, abilities which 
are defined as one of the hallmarks of cancer by Hanahan and Weinberg (146). 
Tumour cells are able to adopt various modes of migration, which involves changes 
in cell morphology, in order to overcome challenging environments during invasion. 
Various modes of cancer cell migration include mesenchymal and amoeboid like 
single-cell migration, multicellular streaming and collective cell migration (147). This 
ability to display heterogeneity is also known as cellular plasticity, and is normally 
observed during development, but has been reported to be displayed by cancer cells 
spontaneously and contributes towards tumour progression (113, 148, 149). Despite 
increased investigations into PDAC in recent years, little is known regarding cellular 
plasticity and the mode of migration of PDAC cells. Uncovering the cellular plasticity 
and the mode of migration of PDAC could lead to novel therapeutic strategies against 
metastatic PDAC cells. 
Recent findings have demonstrated that the tumour microenvironment in PDAC 
contributes towards tumour growth, metastasis and resistance to therapy (150). 
Activated PSCs in the stroma have been demonstrated to induce EMT in pancreatic 
cancer cells, which is correlated with increased metastasis and drug resistance of the 
 58 
tumour (116, 124, 151). Moreover, recent sub-type classification based on gene 
expression has identified correlations with therapeutic resistance and survival rates 
between classical and quasi-mesenchymal (QM) sub-types (53). Thus, given the 
clinical relevance, it is therefore important to take subtyping and stromal interactions 
into account when developing a 3D model for drug discovery in vitro.  
Previously, it has been demonstrated that melanoma cancer cells on 2.5D thick layer 
collagen recapitulates their behaviour in 3D collagen environments (113). It is 
therefore interesting to see whether this is also the case for pancreatic cancer cells. 
Furthermore, investigating the expression of EMT markers such as E-cadherin, N-
cadherin, Vimentin, and the presence of actomyosin contractility could provide 
valuable information regarding cellular plasticity, mode of migration and invasion. It 
has been demonstrated that E-cadherin plays a role in collective cell migration (152), 
while the loss of E-cadherin is often accompanied with EMT (123). In addition, it has 
been well documented that actomyosin contractility affects cell morphology and 
migration in 3D matrix (112, 113, 115, 153).  
The 2.5D model allows for simple morphological analysis and identification of protein 
expression on collagen I matrix, but does not allow the assessment of invasiveness 
of the cells. 3D invasion models such as spheroid invasion assay and the organotypic 
assay provide the possibility to assess invasiveness, 3D cell behaviour and drug 
penetration. However, protein extraction and viability assays are more complicated 
to perform in these 3D models. Combing the use of 2.5D and the 3D models, I can 
characterise cellular morphology and assess cellular invasion in the presence of 
tumour micro environmental and genetic factors.  
This chapter aims to characterize the panel of human pancreatic cancer cell lines with 
in vitro multidimensional models in order to identify a cell line model for the drug 
screen platform. The cell line model should be clinically relevant and highly invasive. 
Furthermore, I will also address cellular morphology and plasticity in pancreatic 




 Cells of quasi-mesenchymal subtype are enriched in single cell events 
In order to determine a suitable cell line model, which is of QM subtype, able to form 
spheroids and is highly invasive in vitro and in vivo, for our drug screen against 
pancreatic cancer discussed in chapter 4 and 5, I first sought to characterise 
pancreatic cancer cell behaviour on the 2.5D collagen I assay (Figures 3-1). Cellular 
morphology in each individual PDAC cell line was investigated by quantifying the 
morphological events and analysing individual cell morphology. Morphological 
events were categorised as single cells, doublet cells or dividing cells, clustered cells 
with 3 cells or more cells, and tight defined colony cells (Figure 3-1 B). The doublet 
cell and cluster cell events could be seen as transition phases between single 
individual cells and when forming tight collective moving colony cells. Phase contrast 
images were taken at 24 and 48 hours and each event was counted manually in 
ImageJ (Figure 3-1C). Cell lines were categorised by origin (primary tumour or 
metastasis), differentiation status (well, moderate and poorly differentiated) and 
sub-type classification (Classical or Quasi-mesenchymal) (Table 3-1)(53). No 
significant differences were found between morphological events at 24 and 48 hours 
post seeding. Furthermore, no differences were found when morphological events 
of cell lines were compared based on origin or differentiation status (Data not shown). 
However, differences were observed in the percentage of single cell and colony cell 
events in the population when cell lines were compared based on sub-type 
classification (Figure 3-2A and B). QM cell lines formed significantly less colonies 
(average 4.7% vs 32.1%) and were more enriched in single cell (average 42.2% vs 
30.1%) events compared to classical cell lines (Figure 3-2B). No significant differences 
were found in the doublet cell or clustered cell events, suggesting that doublet and 
clustered cell events could be intermediate modes between single and colony cell 
behaviour.  
However, differences in the cluster cell event percentages indicate a possibility of an 
extra “subtype” than just the classical and the quasi-mesenchymal ones. The “first 
group” of cells such as Capan2, PaTu8988S and CFPAC1 show high tendencies of 
forming well defined colony cell (average of 39.55%) events with a low percentage of  
Table 3-1: Differentiation state, sub-type classification, source of origin and common genetic alterations of the used PDAC cell lines. 
Cell line Differentiation state Subtype Source of tumour cells KRAS TP53 CDKN2A SMAD4 
CAPAN2 Well (154) Classical (53) Primary tumour (155) 12V (154) WT (154) WT (154) WT (154) 
CFPac1 Moderate (156) Classical (53) Liver metastasis (155) (cystic 
fibrosis patient) 
12V (154) 242R (154) WT (154) HD (154) 
Colo357 Well (157) QM-PDA (53) Celiac lymphnode metastasis  WT (158) WT(158) Meth (158) HD(158) 
HPAC Moderate – well (154) Classical (53)  Primary tumour (154)  12D (154) WT (154) 112stop 
(154) 
WT (154) 
Panc1 Poor (156) QM-PDA (53) Primary tumour (155) 12D (154) 273H (154) HD (154) WT (154) 
Patu8902 Moderate to Poor (159) QM-PDA (53) Primary tumour (159) 12V (160) 176S (160) WT (160) WT (160) 
PaTu8988S Well (161) Classical (53) Liver metastasis (155) 12V (48) 282W (162) N.A. N.A. 
PaTu8988T Poor (161) QM-PDA (53) Liver metastasis (155) 12V (48) 282W (162) N.A. N.A. 
SW1990 Moderate - well(163, 
164) 
QM-PDA (53) Spleen metastasis (163) 12D (165) WT (165) N.A. N.A. 































Figure 3-1. Representative phase contrast images of 2.5D morphological event 
characterisation of classical and quasi-mesenchymal subtype.  
A) Schematic representation of the 2.5D collagen I matrix assay. B) Representative 
images of the morphological events: single cells, doublet cells, clustered cells and 
colony cells C) Phase-contrast images of Capan2 (Classical) and PaTu8988T (Quasi-
mesenchymal) cells on thick layer collagen type I taken at 24hrs and 48hrs post 
seeding. Scale bar= 50µm. 
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Figure 3-2. Morphological events on 2.5D bovine collagen I matrix. 
A) Percentage of morphological events (Colony cell, cluster cell, doublet cell and 
single cell) of individual cell lines on 2.5D bovine collagen I quantified at 48hrs, 
grouped in classical and quasi-mesenchymal subtype. 100% is the sum of all 
morphological events added up. ±SEM, n=3 with 10 morphological events per field, 
out of 3 fields per triplicate, per individual experiment. B) Morphological events 
compared between classical and quasi-mesenchymal subtype. 100% is the sum of all 



























Figure 3-3. Morphological events of three different subtypes on 2.5D collagen I 
matrix. 
Average percentage of morphological events (Colony cell, cluster cell, doublet cell 
and single cell) of each cell line grouped in the three groups of subtypes: Classical 
(Capan2, PaTu8988S and CFPAC1), “Intermediate” (HPAC and Patu8902) and QM 
(Panc1, Colo357, Patu8988T and SW1990). ±SEM, n=3 with 10 morphological events 
per field, out of 3 fields per triplicate, per individual experiment, per cell line. Two-





















































cluster cell formation (average of 8.87%) (Figure 3-3). These cells could be defined as 
strong Classical colony forming epithelial cells and seems to be able to organise 
themselves into a colony in an efficient manner. Despite HPAC and Patu8902 being 
categorised in two distinct subtypes, their morphological behaviours were very 
similar to each other. Cell lines from this Intermediate “second group” readily form 
clustered cells (average of 53.1%), but are not able to organise themselves efficiently 
into a tight collective coordinated colony cell behaviour (average of 9.5%). This may 
suggest that these cells are partially undergoing EMT, demonstrating a more 
transient interaction with neighbouring cells. The QM or “third group”, consisting of 
Panc1, Colo357, Patu8988T and SW1990, show strong single cell behaviour (average 
of 55.2%), but are unlikely to form colonies (average of 3.7%). Cells from this group 
seem to have fully undergone EMT into a mesenchymal phenotype and are staying 
individual for a longer period of time or forms transient group of cluster cells.  
In order to validate the findings observed on 2.5D collagen I matrix, cell lines were 
tracked for 16hrs on 2.5D collagen I matrix between 24 and 48 hrs with time lapse 
microscopy. Cells from classical cell line Capan2 readily forms mini colonies which are 
collectively motile and are able to fuse together into one large collective migrating 
colony (Movies 1). While Capan2 cells demonstrate strong epithelial cell behaviour, 
the “intermediate” and QM cell lines like PaTu8902 and PaTu8988T respectively, 
were not able to organize a cluster of cells into a collective migrating colony (Movie 
2 and 3).  Where PaTu8902 cells are continuously interacting with neighbouring cells 
by adhering and detaching transiently, switching between single, doublet and cluster 
cell behaviour, Patu8988T cells seem to remain individual during majority of the time 
course but are able to transiently form cluster cells as well. Overall, these results 
show that QM cell lines are less likely to stay in colonies and are found as individual 
cells majority of the time compared to classical cell lines. The “intermediate” group 
of cells resembles the QM cell behaviour more closely, revealing the ability to 
transiently form cluster cell events. More cell lines need to be characterised to 
validate the “intermediate” sub-type in combination with future efforts in subtyping 
based on distinct genetic expression profiles correlated with clinical relevance. 
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3.2.2 QM cell lines express mesenchymal markers and demonstrate high levels of 
contractility 
The classical and the QM sub-types were originally defined based on differential gene 
expression (53). As the QM sub-type was correlated with upregulated expression of 
mesenchymal related genes, it was not surprising to observe an enrichment of 
individual cell behaviour in the QM sub-type cell lines. It was therefore interesting to 
investigate whether this phenomenon was related with the EMT process. 
Furthermore, it would be attractive to validate the existence of an “intermediate 
subtype” which I have identified previously.  
Initial differences in E-cadherin expression were observed between Classical, 
“intermediate” and QM cell lines in the 2.5D assay with immunofluorescent staining 
for E-cadherin (Figure 3-4). E-cadherin expression localised at the membrane and at 
the junctions between neighbouring cells in colonies was observed in the Classical 
cell line Capan2, demonstrating the presence of stable junction in colony cells. No E-
cadherin expression was observed in cluster cells or individual cells of the QM cell 
line PaTu8988T. Nevertheless, Junctional E-cadherin expression was observed in 
cluster cells of the ‘intermediate’ cell line PaTu8902. Furthermore, E-cadherin 
localisation was also found at the membrane level of single cells and in leading cells 
of a cluster in PaTu8902 cells. This may suggest that ‘intermediate’ cells such as 
PaTu8902 cells express E-cadherin on the cell membrane to readily form clusters. 
While Classical cells efficiently establish junctions with E-cadherin, QM cells may 
adhere and interact transiently with neighbouring cells through other types of 
junctional proteins. Expression of mesenchymal markers might differentiate the 
three subtype phenotypes further. 
In order to quantify the expression markers and confirm whether ‘intermediate’ and 
QM cells are undergoing or have undergone EMT, western blot analysis was 
performed on selected classical and QM cell lines for the expression of epithelial 
protein E-cadherin, the mesenchymal protein markers N-cadherin and Vimentin 
(Figures 3-5 and 3-6). Furthermore, I also quantified actomyosin contractility markers 
pMLC2 and total MLC2 expression to investigate potential mesenchymal to 

























Figure 3-4. Expression and localisation of E-cadherin in classical and QM cells. 
Representative confocal images of Capan2, PaTu8902 and PaTu8988T cells in 2.5D 
assay on thick layer collagen type I for 48hrs. Staining for DAPI (Blue), E-cadherin 
(Green), F-actin (Red) and merged images are shown. Scale bar= 50µm.  
  

















































Figure 3-5. Western blot of epithelial, mesenchymal and contractility markers of cells 
on plastic and on 2.5D collagen I matrix.  
Cells were lysed at 48hrs and blotted for E-cadherin (epithelial marker), N-cadherin 
and Vimentin (mesenchymal markers) and pMLC2(T18/S19) and total MLC2 
(contractility marker). Β-Actin was used as loading control. Blots shown are 




















































































































Figure 3-6. Quantification of immunoblot detection with densitometry analysis for 
various markers in various cell lines cultured on plastic. 
Immunoblots with expression levels of E-cadherin (epithelial marker), N-cadherin 
and Vimentin (mesenchymal markers) and pMLC2(T18/S19) and total MLC2 
(contractility marker) were quantified through the densitometry analysis with ImageJ. 





























































































































































































































































compared between cells cultured on plastic and on 2.5D collagen I matrix. However, 
no significant differences were found regarding the expression of markers from cells 
cultured on plastic and 2.5D collagen I matrix (Figure 3-5 – 3-6). Although, E-cadherin, 
N-cadherin and Vimentin expression on collagen was consistent with cells cultured 
on plastic, detection of MLC2 and pMLC2 levels of cells cultured on collagens has 
been inconsistent due to technical issues. Therefore, here I focussed on the 
expression of these markers of cells cultured on plastic. 
 E-Cadherin expression was not only observed in Classical cell line such as CFPAC1 
and PaTu8988S, but also in the “intermediate” cell lines HPAC and PaTu8902. QM 
Cells lines Patu8988T and Panc1 did not express E-cadherin, which was consistent 
with the findings observed with immunofluorescence staining of PaTu8988T on 2.5D 
assay. PaTu8988T also expressed N-cadherin whereas Panc1 did not. However, both 
QM cell lines expressed Vimentin, confirming their mesenchymal phenotype. 
Intriguingly, whereas the classical cell line CFPAC1 expressed E-cadherin, N-cadherin 
and Vimentin suggesting an EMT profile, ‘intermediate’ cell lines PaTu8902 and HPAC 
did not express these mesenchymal markers. These data suggest that full classical 
cells such as Capan2 and PaTu8988S demonstrated strong E-cadherin expression, 
while fully transitioned QM cells such as PaTu8988T and Panc1 expressed at least 
one of the mesenchymal markers such as Vimentin paired with loss of E-cadherin 
expression. The identification of “intermediate” cells by utilising these markers 
remains complex and warrants the use of additional markers to subcategorize the 
classical cell lines undergoing EMT and the “intermediate” cells. 
Next, I also investigated the possibility of cells that have undergone MAT, especially 
in QM cells. High levels of double MLC2 phosphorylation (pMLC2 T18/S19) was 
observed in majority of the cell lines (Figure 3-5 and 3-6). HPAC and PaTu8988S 
showed lower levels of MLC2 phosphorylation compared to the QM cell lines and the 
classical EMT cell line CFPAC1. The phosphorylation levels were accompanied with a 
lower total MLC2 expression in both HPAC and PaTu8988S cell lines. While the QM 
cell lines and the EMT cell line CFPAC1 demonstrated high levels of pMLC2, the 
relative MLC2 phosphorylation (pMLC2/MLC2) remains similar across the cell panel, 
indicating similar levels of “engagement” of contractility have been present in each 
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individual cell line. Nevertheless, the overall contractile forces that these cells exert 
would be higher compared to HPAC and PaTu8988S.  
In order to confirm the findings from the immunoblot analysis, a gene set enrichment 
analysis (GSEA) for contractile genes identified previously by Sanz-Moreno et al was 
conducted with QM and Classical cells in collaboration with Dr. Irene Rodriguez 
Hernandez from Sanz-Moreno lab (Figure 3-7) (112). Gene expression in QM cells 
such as Panc1, SW1990 and PaTu8988T were enriched for genes associated with 
actomyosin contractility, whereas classical cells like Capan2 and PaTu8988S were 
correlated with downregulation of these target genes. This data further supports the 
distinction in the contractile profile between Classical and QM cells, suggesting 
contractility as a biomarker for identifying QM subtype cells. 
Overall, these results demonstrate that EMT and contractility markers can distinguish 
QM from the classical cells. Classical cells demonstrated E-cadherin expression 
localised to the junctions and have lower overall contractility. Furthermore, we also 
identified cells undergoing EMT, like the CFPAC1, through the expression of E-
cadherin, N-cadherin and Vimentin, with high levels of MLC2 phosphorylation. 
However, GSEA data suggested that the contractile machinery is not as upregulated 
in CFPAC1 as in QM cells, confirming its subtype as Classical cell line. QM cells showed 
expression of Vimentin with or without N-Cadherin, which was also paired with high 
levels of MLC2 phosphorylation. Furthermore, QM cells were shown to be 
significantly enriched in genes associated with a contractile expression profile. 
Nevertheless, the expression profiles of previous suggested ‘intermediate’ cell lines 
were not differentiated from either the QM or the Classical expression profiles based 
on the markers used here. As more work is needed to confirm the existence of the 
“Intermediate” subtype, I therefore continued with the reported Classical and QM 




























Figure 3-7 Gene set enrichment analysis of Classical and QM cells for contractile 
genes. 
GSEA plots comparing QM and Classical cell lines based on expression of contractile 
genes identified by Sanz-Moreno et al with accession numbers GSM586484–
GSM586501 (112). Only gene expression data of QM and Classical cell lines 
conducted with the same platform and in the same experiments were used. Note: 
data and analysis generated by Dr. Irene Rodriguez Hernandez. 
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3.2.3 Individual pancreatic cancer cells adopt a round morphology and 
demonstrate cellular plasticity 
Since QM cell lines were more enriched in individual cells and demonstrated high 
levels of MLC2 phosphorylation in the overall cell population, it was logical to 
characterise the individual cells based on morphology and also to investigate 
whether there were differences in the individual cell population between Classical 
and QM cell lines. The roundness of each individual cell on 2.5D collagen was 
analysed with ImageJ using the roundness parameter (Figure 3-8). Cells were more 
elongated with roundness values closer to zero while cells were more round with 
values closer to 1.  
A round cell morphology was adapted by majority of individual cells of all cell lines, 
except for SW1990, which demonstrated a mixed population distribution of round 
and elongated individual cells. As a consequence of these results, no differences 
were found when the data was either clustered based on cell line origin, 
differentiation status or sub-type classification (Figure 3-8B to D). These results were 
validated and confirmed by analysing the roundness of individual cells with F-actin 
immunofluorescence staining on 2.5D collagen I matrix (Data not shown), supporting 
the robustness of the phase contrast analysis method. 
However, a subset of mesenchymal individual cells was found in certain cell lines 
such as the PaTu8988T and the SW1990 (Figure 3-8). It was therefore interesting to 
assess whether certain pancreatic cancer cells exhibit cellular plasticity. Time-lapse 
microscopy revealed that certain PaTu8988T, SW1990 and CFPAC1 cells in the 
population were able to switch between round and elongated cells on the 2.5D 
collagen I matrix (Figure 3-9A and Movie 4 to 6), demonstrating cellular plasticity. 
Although Capan2 and PaTu8902 cells mainly adopted a round morphology (Figure 3-
8), time lapse movies showed the presence of plasticity in single cells, which seemed 
to be very transient and adopted a round morphology majority of the time (Figure 3-
9B and Movie 7 and 8). These results demonstrate that individual pancreatic cancer 
cells are mostly round and exhibit cellular plasticity, able to transiently switch 




















Figure 3-8. Single cell morphology on 2.5D bovine collagen I matrix.  
A) Roundness of individual cells were measured with ImageJ at 48hrs post seeding, 
with an index of 1 being round and 0 being elongated. Data presented are the mean 
± S.E.M of 3 independent experiments, with each individual data point representing 
an individual cell. All individual cells in duplicate fields were analysed per experiment. 
B) Comparison of Individual cell roundness by subtype: classical and quasi-
mesenchymal subtype cells, C) by cell origin: primary and metastasis derived cell lines, 
and D) by differentiation status: well, moderate or poorly differentiated. Data 


























































































































































































































Figure 3-9. Cellular plasticity of pancreatic cancer cells on 2.5D collagen I matrix 
A) Time lapse movie of individual PaTu8988T, SW1990 and CFPAC1 cells with frames 
taken at 0, 120, 240, 360 and 480 minutes. B) Time lapse movie of individual 
Patu8902 and Capan2 cells with frames taken at 0, 120, 240, 360 and 480 minutes. 








































3.2.4 Individual pancreatic cancer cells are contractile and are able to bleb 
As majority of the individual pancreatic cancer cells were round by morphology, it 
was noteworthy to see if there were differences between them. Beside round 
epithelial cells there are also round amoeboid cells. Previously I have demonstrated 
that the QM cells had higher contractility compared to classical cells, through 
immunoblot detection of MLC2 phosphorylation in whole cell lysates and gene set 
enrichment analysis for contractile genes (Figures 3-5 to 3-7). This approach did not 
distinguish the contractility of single cells and cluster or colony cells. Therefore, we 
utilised immunofluorescence staining and confocal imaging of individual cells on 2.5D 
collagen I to identify pMLC2 levels and bleb formation (Figure 3-10A). pMLC2 levels 
of individual cells were quantified by ImageJ using the corrected total cell 
fluorescence (CTCF or total corrected cell fluorescence (TCCF)) method (Figure 3-10B) 
(166). Phosphorylation of MLC2 was present in all individual cells, with varying 
intensities. PaTu8902 showed the highest average intensity of pMLC2, whereas 
Panc1 had the lowest average intensity of pMLC2. However, no significant 
differences were found when we compared Classical individual cells against QM 
individual cells (Figure 3-10C).  
To further identify which cell lines individually undergone MAT and became 
amoeboid, I investigated the formation of blebs in the individual cells (Figure 3-11A). 
All cell lines were able to form blebbing cells, except for PaTu8902. Patu8988T had 
the highest proportion of blebbing cells among its single cell population. We then 
compared the ability of bleb formation in single cells between Classical and QM cells 
(Figure 3-11B). The data suggests that single cells of QM subtype have a higher 
tendency to form blebs, however this was not significant, due to large variances in 
the QM population.  
Although QM cells and CFPAC1 demonstrated high levels of contractility, this was not 
reflected back in the individual cell population. Nevertheless, all cells demonstrated 
contractility while only Patu8902 did not utilise blebs, despite having the highest 
intensity for MLC2 phosphorylation, suggestion an alternative high contractility 
movement. Indeed, when investigating the PaTu8902 morphology further, the 
formation of pseudopods by the cell line has been identified, while maintaining cell 
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contractility (figure 3-11C). Furthermore, this alternative subtype of the amoeboid 
phenotype was observed in majority (85%) of the round PaTu8902 individual cell 
population, suggesting that this is the preferred mode for PaTu8902. Future single 




















Figure 3-10. Contractility levels of individual cells on 2.5D collagen I matrix. 
A) Representative Immunofluorescence images of Individual cells from classical 
(Capan2) and quasi-mesenchymal (PaTu8988T) subtype with bleb formation on 
Collagen I matrix. Localisation of F-actin (red), nucleus (blue) and pMLC2 (S19) (Green) 
were visualised by immunofluorescence staining. Scale bar= 5uM. B) Quantification 
of pMLC2 (S19) fluorescent intensity of individual cells of each cell line with ImageJ. 
Data presented are the Median with range of 3 independent experiments with 
individual dots representing single cell data. All individual cells in 5 fields were 
analysed per experiment. C) Quantification of pMLC2 (S19) fluorescent intensity of 
classical (Capan2, PaTu8988S, CFPAC1, HPAC) and quasi-mesenchymal (Panc1, 
Colo357, PaTu8988T, SW1990) subtype grouped together. Data presented are the 
Median with range of 3 independent experiments with individual dots representing 
single cell data of cell lines from each experiment. No statistical significance was 





































































































































Figure 3-11. Individual cells with bleb or pseudopod formation on 2.5D Collagen I 
matrix.  
A) Percentage blebbing cells in the individual cell population of cell lines after 48hrs 
on 2.5D collagen I matrix. Data presented are the average mean ±SEM of n=3 B) 
Percentage individual blebbing cells of classical (Capan2, PaTu8988S, CFPAC1, HPAC) 
and quasi-mesenchymal (Panc1, Colo357, PaTu8988T, SW1990) subtype. Data 
presented are the average mean ±SEM of n=3. C) Representative 
Immunofluorescence image of PaTu8902 round individual cell with pseudopods. 
Staining for DAPI (Blue), pMLC2 (S19) (Green), F-actin (Red) and merged images are 
shown. Scale bar= 10uM D) Percentage of round individual PaTu8902 cells forming 
pseudopods. Data presented are the average mean ±SEM of n=3. All individual cells 
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3.2.5 QM cells readily form co-culture spheroids more likely over classical cells 
To further characterise the cell lines and to validate a cell line model suitable for the 
drug screen against pancreatic cancer, I conducted functional assays to determine 
their invasiveness and ability to form compact spheroids. Cells were co-cultured with 
pancreatic stellate cells PS-1 in a round bottom ultra-low attachment spheroid 
formation plate to assess their anchorage independent growth and spheroid 
formation (Figure 3-12) (142). The formed spheroids were defined as spheroids when 
the spheroids did not easily fall apart after gentle resuspension. Classical cell lines 
HPAC and PaTu8988S were able to form a single co-culture spheroid over a time 
course of 3 days, while Capan2 and CFPAC1 were unable to form a single spheroid 
and instead showed the formation small clumps which expanded over the time 
(Figure 3-12A). All the assessed QM cell lines were able to form a single co-culture 
spheroid with PS-1 except for SW1990, which demonstrated similar clump formation 
behaviour as Capan2 and CFPAC1 (Figure 3-12B). It was also observed that certain 
cells are better in forming perfectly round tight spheres such as HPAC, PaTu8988S, 
PaTu8902, Clo357 and Panc1 compared to the spheroid like structure of Patu8988T. 
Nevertheless, QM cells seem to more likely form spheroids (4 out of 5 cell lines; 80%) 
compared to Classical cells (2 out of 4 cell lines; 50%) (Figure 3-12C), which reflects 
their aggressiveness and correlates with poorer prognosis in the clinic. More cell lines 




























Figure 3-12. Spheroid formation ability of classical and quasi-mesenchymal subtype 
cells. 
A) Spheroid formation of classical cell lines Capan2, CFPAC1 (non-spheroid), HPAC 
and PaTu8988S (Spheroid), and B) quasi-mesenchymal cell lines PaTu8902, 
PaTu8988T, Colo357, Panc1 (Spheroid) and SW1990 (non-spheroid) with PS-1 are 
shown at 24hrs and 72hrs. Scale bar = 100μm. C) The percentage of spheroid 
formation ability of cells from classical (4 cell lines) and quasi-mesenchymal (5 cell 


































































































3.2.6 QM cells are more invasive in the spheroid invasion assay 
As QM cells were more likely to form co-culture spheroids with PS-1 stellate cells, it 
was of importance to confirm whether these cells are more aggressive by 
invasiveness in 3D matrix. I investigated the invasiveness of the co-culture spheroids 
in 3D collagen I matrix by using growth medium with 10% FBS as chemoattractant 
(Figure 3-13 and 3-14). Classical cell line PaTu8988S showed a collective invasion 
after 4 days, but no dissemination of invading individual cells (Figure 3-13A). QM cell 
lines PaTu8902 and PaTu8988T showed high invasion of disseminated single cells. 
PaTu8902 disseminated as single cells, whereas PaTu8988T invaded in round and 
mesenchymal cells as characterised previously in the 2.5D assay (Figure 3-8B).  
The average invaded distance per quadrant and the average spheroid body diameter 
was then quantified in ImageJ as invasion and invasive growth parameters (Figure 3-
14). QM cells PaTu8902 (886.9 μm) and PaTu8988T (780.6 μm) showed high invasion, 
compared to the other cell lines. Moreover, when I compared the ability of QM cell 
lines to Classical cell lines in 3D invasion, QM cells was shown to be significantly more 
invasive starting from day 3 (Figure 3-14B). In addition, I have also conducted a 
qualitative assessment of the spheroid invasive behaviours, categorised in single cell 
invasion, collective colony invasion and collective cell invasion (Table 2). Single cell 
invasive behaviour seems to affect the invasive distance positively, while having high 
collective invasive behaviour seems to decrease the invasive distance.  
Nevertheless, the highest invasive cell lines where not the highest spheroid growers, 
demonstrating lower relative invasive growth of the spheroidal body (Figure 3-14A). 
Panc1 was shown to be the cell line with the highest relative invasive growth, while 
this did not correlate with the invasion observed earlier. Furthermore, when QM cells 
were compared against Classical cells, no significant increases in relative spheroidal 
growth were found (Figure 3-14B). These data suggest that QM cells are more 
invasive compared to Classical cells and this is not correlated with or affected by the 
relative spheroid growth observed for the cell lines.  Furthermore, PaTu8902 shown 
to be the most aggressive and invasive cell line of QM subtype among all the tested 
cell lines, demonstrating single cell and collective invasion, and could therefore be a 

























Figure 3-13. invasion of Spheroids in 3D rat tail collagen I matrix. 
A) Representative phase contrast images of PaTu8988S, PaTu8902 and PaTu8988T 
co-culture spheroid invasion at 0 and 4 days in 3D collagen I matrix. Scale bar= 100μm. 













































Figure 3-14. Spheroid growth and invasion in 3D rat tail collagen I matrix. 
A) Quantification of average invaded distance per quadrant in μm and the relative 
spheroidal growth measured by the average size of the diameter of the spheroid 
body of the individual cell lines. B) Quantification of average distance invaded of 
furthest cells per quarter per triplicate in an individual experiment. Two Way 
ANOVA with Tukey’s post hoc test was used for statistical significance. **, P<0.01. 
Data presented are the mean ± S.E.M, N=3.   
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Collective invasion Retains 
spheroid body 
Morphology d0 Average total 
distance 
invasion in μm 
Invasiveness 
HPAC Classical Primary + + ++ Yes Sphere 371.1 Low 
Patu8988S Classical Metastasis - - + Yes Sphere 65.0 Low 
Patu8902 QM Primary ++++ - + Yes Sphere 886.9 High 
Patu8988T QM Metastasis ++++ - + Yes/No Spheroid 780.6 High 
Panc1 QM Primary ++ - ++ Yes Sphere 338.3 Low 
Colo-357 QM Metastasis + - +++ Yes Sphere 264.2 Low 
- Not present, + Present, ++ Mainly Present, +++ Highly Present, ++++ Abundantly present 
Single cell invasion: Single cells disseminate from the spheroid body 
Collective colony invasion: Colonies/groups of cells disseminate from spheroid body 
Collective invasion: Non-disseminated collective invasion from the spheroid body 
 
Table 5 Quantitative and qualitative data of cells in the spheroid invasion assay 
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3.2.7 Validation of PaTu8902 invasive behaviour in other models 
In order to investigate whether PaTu8902 would be the ideal representative cell line 
model for the drug screen, I validated the findings of PaTu8902 from the 2.5D assay 
and the spheroid invasion assay with an alternative approach. The PaTu8902 cell line 
was tested in the 3D mini organotypic assay, a miniature version of the conventional 
organotypic assay (141, 167) (Figure 3-15). PaTu8902 cells were able to form an 
organised epithelial layer with luminal structures present in the absence of PS-1 
stellate cells (Figure 3-15A and B). Furthermore, no single cell and collective cell 
invasion were observed. However, when PS-1 was introduced in a 2:1 ratio between 
PS-1 and PaTu8902 cells, an increase in the thickness of the epithelial layer was 
observed, suggesting a form of invasive growth. The PaTu8902 cells also seemed to 
be larger than when they were cultured without PS-1 cells. In addition, majority of 
the PaTu8902 cells seemed to adopt a round morphology and even invaded into the 
matrix as single cells too (Figure 3-15A; white arrows). PS-1 cells were found to form 
a layer in between the matrix and the epithelial layer, with several PS-1 cells invading 
into the matrix as well (Figure 3-15A and B). These findings demonstrated that 
PaTu8902 cells in the 3D mini organotypic assay recapitulated the round morphology 
observed in the 2.5D assay. Furthermore, their invasiveness was also confirmed in 
the form of collective invasion and single cell invasion when co-cultured with PS-1, 






Figure 3-15. Invasion of PaTu8902 in the presence of PS-1 in the organotypic assay. 
A) Confocal images of organotyic assays with PaTu8902 cells (Stained with 
Cytokeratin in Green) in the presence and absence of PS-1 stromal cells (Stained with 
α-Smooth muscle actin in Red) after 7 days. Dashed line indicates the matrix surface 
and arrows indicate invading Patu8902 cancer cells. Scale bar = 50μm B) Hematoxylin 
and Eosin staining of organotypic assays in the presence and absence of PS-1 stromal 
cells after 7 days. Scale bar = 100μm  
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In this chapter, the human pancreatic cancer cell lines were characterised in order to 
understand pancreatic cancer better and identify a representative cell line in co-
culture with PS-1 stellate cells to perform the drug screen on. Little has been 
reported regarding the cellular morphology, plasticity, contractility and the preferred 
mode of migration of pancreatic cancer cells, especially in 2.5D or 3D matrix. 
Furthermore, the reported genetic subtypes by Collisson et al have not previously 
been correlated with any morphological or phenotypical characteristics in vitro in 
pancreatic cancer. Nevertheless, the use of molecular subtyping as survival and 
therapeutic response predictors has recently been further validated in pancreatic 
cancer (168, 169). A recent study on metabolic clustering utilising the subtype 
classification by Collisson et al was able to demonstrate metabolic differences 
between the two subtypes (169). QM cells were associated with a glycolytic 
metabolic subtype, while Classical cells were associated with a lipogenic metabolic 
subtype, suggesting functional relevance between genetic subtypes and distinct 
responses to targeted inhibitors.  
Two other subtype classification papers have been published since the start of my 
study, supporting the existence and classification of these subtypes (37, 59). The QM 
subtype identified by Collisson et al 2011 has been reported to correspond with the 
basal subtype identified by Moffitt et al, and the squamous subtype identified by 
Bailey et al, (37, 59). Furthermore, both reported that the basal and the squamous 
subtype were correlated with a poor survival compared to the other subtypes 
identified in their respective studies. In this study, the QM subtype was shown to be 
enriched for single cell behaviour and reduced colony formation ability, which was 
correlated with the expression of mesenchymal markers and increased invasive 
capabilities compared to the Classical subtype. These findings were consistent with 
studies of the basal subtype in breast and bladder cancer, which have been reported 
to be more aggressive, demonstrating increased invasive behaviour and adopted an 
EMT or mesenchymal phenotype, expressing vimentin and losing E-cadherin 
expression (170, 171). Moreover, several independent studies have demonstrated 
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the expression of Vimentin and loss of E-cadherin in QM cells such as Panc1 and 
PaTu8988T, further supporting their mesenchymal profile (172, 173).  
Despite the presence of distinctive molecular subtypes, here I report that the general 
individual pancreatic cancer cell demonstrates cellular plasticity, being able to switch 
between a round and an elongated morphology. Strikingly, cellular plasticity in 
pancreatic cancer has previously mainly been reported in the acinar cells, allowing 
these cells to transdifferentiate, lose polarity and break away from the acinus during 
inflammation, injury and tumour development (7). These acinar cells have been 
identified as one of the origins of pancreatic cancer and readily undergo 
transformation upon Sox9 expression and mutant Kras signalling through PI3K-PD1 
pathway, indicating the important role of cellular plasticity in PDAC progression (8, 
45). Furthermore, a recent study has shown that loss of Smarcb1, a chromatin 
remodelling factor, activates myc in Kras independent cancer cells to undergo EMT 
transformation into a more aggressive and metastatic mesenchymal phenotype 
(174). In addition, it has also been shown that the cellular plasticity in pancreatic 
cancer cells from genetic engineered mouse models (GEMM) is regulated by the EMT 
transcription factor Zeb1 (129). Moreover, another study has shown that E-cadherin 
positive and E-cadherin negative pancreatic cancer cells could both give rise to 
tumours in vivo, demonstrating plasticity between the epithelial and the 
mesenchymal states of the cancer cells (130). These findings are in line with our data 
in vitro, demonstrating the existence of cellular plasticity in pancreatic cancer and is 
more prominent in QM subtype cells. This ability reflects the acinar to ductal 
metaplasia plasticity process through EMT and indicates an aggressive phenotype of 
cells that is able to switch morphology for survival and migration.  
The EMT- MET process is an example of cellular plasticity. It has been well established 
that EMT and mesenchymal cells are correlated with an elongated mesenchymal 
morphology, while epithelial or amoeboid cells are adopting a round morphology 
(175, 176). Here, I have found that individual cells of all pancreatic cancer cell lines 
adapted a round morphology on 2.5D collagen I matrix majority of the time, 
disregarding the subtype. Intriguingly, this finding is consistent with a recently 
published study where the morphology of single cells from primary pancreatic cancer 
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patients on 2D and 3D substrates were analysed and found to be mainly circular (177). 
However, they also showed that cancer cells derived from the primary tumour site 
were more heterogeneous compared to cancer cells derived from a metastatic site 
in the liver. While my results demonstrated a slight trend towards a mixed population 
in the cell lines of metastatic origin, these differences were deemed insignificant. This 
might not be very surprising as the authors have identified a heterogeneity in mainly 
round structures, with a few rare elongated morphologies, which is consistent with 
my findings (177).  
The amoeboid mode of movement is characterised by a round morphology with high 
contractility (176). Two subtypes of amoeboid movement have been characterised 
(178, 179). One of the subtypes is characterised by rounded cell migration with bleb 
formation for a pushing movement and lack of adhesion. The other subtype is 
characterised by a slightly more elongated round cell migration with low substrate 
interaction through the formation of actin- rich filopodia/pseudopodia at the leading 
edge. The amoeboid mode of invasion has been identified to be primarily present at 
the invasive front of primary melanoma and breast cancers, and is enriched in 
melanoma metastases (180-182). As majority of individual pancreatic cancer cells 
exerted a round morphology, I investigated whether individual pancreatic cancer 
cells were utilising this high contractile strategy for migration and invasion. Thus far, 
no one has demonstrated the ability of pancreatic cancer to adopt an amoeboid 
morphology. A recent intravital study in the KPC mice has demonstrated the 
presence of only mesenchymal mode of migration in the pancreatic tumour (183). 
Interestingly, my data demonstrated the presence of mainly round individual cells on 
the 2.5D assay, with a subset of mesenchymal cells. Furthermore, individual cell 
dissemination of both round and elongated cells was observed in the 3D spheroid 
invasion assays of PaTu8902 and PaTu8988T, supporting the presence of round 
invading cells beside the reported mesenchymal morphology in the literature. 
Despite similar pMLC2 levels were observed in individual Classical and QM cells, QM 
subtype cells showed a higher trend of bleb formation in single cells. Furthermore, 
the pMLC2 levels were higher in QM and EMT cell lines in total cell lysates by western 
blot analysis, suggesting a more contractile blebbing amoeboid phenotype in the QM 
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cells. It has been reported that an increase of cellular contractility in pancreatic 
cancers, marked by increased pMLC2 levels through elevated activity of the JAK-
STAT3 signalling cascade, has been correlated with poor survival, increased 
aggressiveness and increased invasion (184). The authors also suggested that the QM 
subtype was correlated with this increased contractile phenotype. Indeed, the GSEA 
data confirmed the enrichment in gene expression of contractile genes in QM cells 
compared to Classical cells. Nevertheless, future gene expression analysis should be 
conducted with genes extracted from cells cultured on Collagen I matrix to further 
support the morphological and phenotypical findings on 2.5D collagen I matrix. These 
findings are in line with my findings, correlating increased cellular contractility with 
increased aggressiveness, and suggesting the presence of amoeboid mode of 
migration and invasion in pancreatic cancer. 
Cellular contractility has also been implicated in spheroid formation (185, 186). Here 
I have shown that QM cells were better at forming spheroids compared to the 
Classical cells. A study in ovarian cancer has shown that mesenchymal cells and cell 
contractility were factors which positively correlated with successful spheroid 
formation and invasiveness in 3D collagen I (187). Furthermore, they have also 
demonstrated that E-cadherin and N-cadherin expression did not predict the 
likeliness of spheroid formation. These findings are in line with my observations in 
this study, demonstrating that QM cells form better spheroids compared to the E-
cadherin expressing Classical cells.  
However, another study has shown that inhibition of actomyosin contractility 
through ROCK inhibitor Y-27632 and blebbistatin (myosin II inhibitor) increased 
spheroid formation and upregulated CD44 in colon cancer cells (188). These CD44high 
cells were correlated with increased spheroid formation ability, increased cancer 
stem cell markers and increased glycolytic activity. Interestingly, CD44 has been 
shown to be a receptor for MMP9 and positively regulates actomyosin contractility 
in amoeboid melanoma cells through stimulation of ROCK signalling (115). Yet, ROCK 
inhibition by Y-27632 demonstrated increased spheroid formation abilities in ovarian 
cancers and glioblastomas, but upregulated other stem cell markers such as Sox2 
instead of CD44 (189, 190).  
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Nevertheless, recently developed ROCK inhibitors such as GSK269962a or AT13148 
has been shown to be more potent in inhibiting ROCK activity compared to Y-27632, 
suggesting that ROCK inhibition by Y-27632 is only partial (108). AT13148 and 
GSK269962a was able to completely inhibit cell contractility and migration. Partial 
inhibition of ROCK allows cells to switch from an amoeboid phenotype to a 
mesenchymal phenotype during migration and has been shown to be insufficient to 
inhibit cellular contractility and proliferation (113, 191). The partial inhibition of 
ROCK activity by Y-27632 may improve spheroid formation by increasing cell 
adhesion as reported previously in trabecular meshwork cells (192). Further studies 
with potent ROCK inhibitors, myosin II inhibitor blebbistatin and knockdown 
constructs in pancreatic cancer will further elucidate the mechanism and role of 
actomyosin contractility in spheroid formation. 
Overall, this chapter demonstrates that PaTu8902 could be a suitable cell line for the 
drug screen as it is a QM cell line, which has been correlated with poor patient 
survival (53). The spheroid invasion assay has identified two high invading QM cell 
lines: PaTu8902 and PaTu8988T. Both cell lines have been reported to be invasive 
(159, 193). Although both QM cell lines demonstrated cellular plasticity, high 
invasiveness and robust single cell dissemination, the PaTu8902 cell demonstrated a 
more robust co-culture spheroid formation with PS-1 stellate cells compared to the 
PaTu8988T cell line. Strikingly, PaTu8902 demonstrated a round morphology in 
individual cells with high pMLC2 levels, but without bleb formation, unlike the 
PaTu8988T. However, PaTu8902 has shown to generate pseudopodial structures 
while maintaining a round morphology (Figure 3-9B), which could be classified as 
amoeboid with pseudopodia/diplopodia mode of migration (179). The invasiveness 
and effective cross talk ability with stromal cells has been validated in the 
organotypic assay for Patu8902, increasing its validity by confirming its aggressive 
phenotype. Moreover, PaTu8902 is the only QM cell line reported by Collisson et al 
to be resistant to gemcitabine (53). This would also take into account the drug 
resistance characteristics observed in pancreatic cancers for the drug screen. These 
findings overall suggest that PaTu8902 would be the choice of cell line model for the 
drug screen with PaTu8988T as a potential back up cell line for validation.  
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3.4. Future work 
This work demonstrated how genetic subtypes are morphologically and 
phenotypically different. It was interesting to observe another sub category, the 
“intermediate” class, during classification by morphology. Additional cell lines could 
potentially uncover more sophisticated subtype classification that is not only based 
on genetic expression, but also on morphological and phenotypical assessment. Also, 
the current subtyping studies are conducted on cells grown on plastic. Future genetic 
studies should be carried out on cells grown on 2.5D assay or in 3D collagen to 
validate these findings. Taking this further with primary cells from pancreatic patients 
could provide us a better understanding of the molecular and phenotypical relations 
and predict survival and treatment response more accurately. 
Genetic expression data does not directly translate into changes on protein levels 
due to post translational modification. Therefore, increased investigation in EMT 
markers (e.g. Zeb1 and Twist1), mesenchymal markers (e.g. αSMA), integrins (e.g. 
β1), and other cell-cell adhesion molecules could shed new light into the molecular 
classification and correlate this with cellular plasticity and the original set of genes 
used for the genetic expression analysis by Collisson et al (53).  
Exciting observations have been made with cellular contractility in the investigated 
cell lines. It would be important to confirm the enrichment of contractile genes for 
all the studied QM cells cultured on Collagen I compared to Classical cells. Future 
work with ROCK inhibitors, Blebbistatin and myosin light chain knock down 
experiments would further pin down the differences in the contractility mechanisms 
between Classical and QM cells. Furthermore, confirming the JAK-STAT3 signalling 
activity might provide further information regarding the contractile machinery and 
the intensity between classical and QM cells. Moreover, the differences in collective 
cell contractility needs to be taken into account, especially when investigating the 
effects on spheroid formation. In addition, it is important to identify whether there 
is a link in pancreatic cancer between ROCK activity, spheroid formation and the 
upregulation of cancer stem cell markers/enrichment of cancer stem cells as found 
in colorectal, ovarian and glioblastoma cancers. 
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To further bridge genetic analysis with functional outcome, it would be of interest to 
investigate the common genes regulated in the QM cells that are responsible for 
contractility and the invasive behaviour in 3D for targeted drug discovery. In addition, 
secreted factors could be screened for MMPs and other ECM degrading enzymes. 
Here I have used a surrogate marker for cellular proliferation by measuring the 
spheroid body expansion. However, it would be very interesting to test and optimise 
the proliferation and cell death in spheroids in 3D to confirm these findings. 
Also, as mentioned previously, pancreatic stellate cells have been reported to play 
an important role in the progression of the disease. I have demonstrated that PS-1 
increased the aggressive phenotype of PaTu8902 in the organotypic assay. It is 
therefore exciting to dissect the effects of PS-1 further by generating conditioned 
medium with and without being in co-culture with cancer cells and investigate the 
effects of the secreted factors in the morphology and invasion studies. 
The ultimate validation for PaTu8902 cells would be recapitulating all the in vitro 
findings with an in vivo mouse xenograft model and confirm these morphological and 
phenotypical findings in patient tissue sample. A drug screen study targeting specific 
markers of Classical or QM subtype cells could be potentially of interest for the 
advancements towards personalised medicine for pancreatic patients. 
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 Development of a 3D spheroid invasion drug screening assay 
4.1. Introduction 
In the previous chapter, I have identified a QM cell line model that is robust in 
spheroid formation and is highly invasive to be used for the drug screen. In order to 
avoid advancement of local invasion or progression to metastatic state of the disease, 
it is important to not only inhibit the invasion of cancer cells, but also be able to 
target and kill local invasive cells and cells that are disseminating systemically. By 
identifying potential migrastatic drugs and combine them with the standard of care; 
Gemcitabine, a cytostatic drug, invasive cancer cells could potentially be targeted 
and killed (194). As mentioned previously, the tumour microenvironment has been 
implicated in tumour initiation, growth and invasion (195, 196). Including the tumour 
microenvironment compartments into the drug screen platform could potentially 
increase the clinical relevance of the drugs and may provide novel therapeutic 
strategies against pancreatic cancer.  
Several methods have been developed to investigate the effects of the tumour 
microenvironment components on pancreatic cancer progression. Co-cultures of 
cancer cells with stromal cells or conditioned medium derived from stromal cells in 
vitro was one of the earlier models used to study the effects of stromal cells on 
pancreatic cancer progression (197, 198). However, transcriptomic studies in various 
cancers, including pancreatic cancer, have demonstrated altered expression of 
proliferation, cell survival or drug resistance related genes when cancer cells were 
cultured as 3D spheroids compared to the conventional 2D plastic culture (199-202). 
Furthermore, the simplicity of 2D culture limits the experimental possibilities and 
lacks the ability to investigate cellular invasion. Moreover, other 3D culture methods 
such as organotypics and the recently developed organoids have demonstrated to 
recapitulate in vivo observations more closely (203, 204). In addition, organoids are 
able to retain the primary phenotype and genetic expression profile for longer 
periods in culture and readily adapts structures resembling the original cancer when 
transplanted orthotopically in vivo (204-206). A 3D approach would therefore be 
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more desirable for studying the contributions of the tumour microenvironment on 
tumour progression over 2D methods. 
Although genetic engineered mouse models (GEMMs) and patient derived 
xenografts (PDXs) are well established models to study the disease progression and 
the role of the tumour microenvironment in vivo/ex vivo, not every laboratory has 
access to mouse facilities and patient materials (203, 207-209). Furthermore, despite 
their power in late stage pre-clinical drug development and personalised medicine, 
these models are often unsuitable for high throughput drug screening due to the 
relative high cost, long experimental duration, the need of many mice and the lack 
of uniform tumour development and progression. Hence, 3D models are more 
favourable as a screening alternative due to their close resemblance of in vivo 
behaviour, high reproducibility, relative low cost, high adaptability and experimental 
feasibility, and scalability for high throughput drug screening (206, 210, 211). By 
utilising 3D models to bridge the gap between 2D and in vivo GEMM or PDX models 
for early phase drug discovery, it would be possible to perform high throughput drug 
screening in the presence of tumour microenvironmental components.  
While the organoids and organotypic assays are more novel compared to the older 
spheroid assay, the spheroid assay is yet more straight forward, time and cost 
effective. Organoids require the use of primary cells either from mouse or human 
patients in order to form long lasting self-renewing organoids with differentiation 
potential (204). The organotypic assay requires the need of tissue processing in order 
to examine the outcome (167). Recent 3D spheroid drug screening models have been 
readily adapted to investigate proliferation, cell survival and cell invasion (212-214). 
Furthermore, co-culture systems have also been implemented in 3D spheroid 
cultures.  A 3D pancreatic cancer co-culture spheroid model with fibroblasts has been 
shown to increase cell survival compared to 2D co-culture systems, demonstrating 
the significance of the 3D architecture (215). Therefore, the spheroid assay could be 
a good model to perform a drug screen while including stromal cells and extracellular 
matrix found in the tumour microenvironment in pancreatic cancer. 
It has been reported that activated pancreatic stellate cells (PSCs) in the tumour 
microenvironment are supporting proliferation, survival, invasion, metabolism and 
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drug resistance of the cancer (102, 141, 216, 217). PSCs would be an important factor 
to be included in drug screens. Strikingly, no drug screens have been performed on 
pancreatic cancer in the presence of stellate cells thus far. Furthermore, as majority 
of the drug screens performed on pancreatic cancers were mainly based on cell 
survival or cell proliferation, no study has been reported on drug screening against 
pancreatic cancer invasion with pancreatic stellate cells in 3D models (206, 218, 219).  
Pancreatic cancer is characterised by desmoplasia, with dense extra cellular matrix 
deposition, majority consisting of Collagen I fibres (220). An increase in collagen 
expression has been associated with increased metastasis and poor prognosis. Using 
Collagen I as the extra cellular matrix in the assay would increase the clinical 
relevance of the model. Another widely used matrix is Matrigel, produced by from 
Engelbreth-Holm-Swarm mouse sarcoma cells. It is widely used to mimic the 
basement membrane matrix in vivo and has shown to play an important role in the 
invasion of pancreatic cancer cells (221, 222). Moreover, pancreatic organoid 
cultures rely on Matrigel to propagate and retain its in vivo characteristics, 
demonstrating the important role of the matrix on supporting pancreatic cancer 
progression (205). Both matrices will therefore be tested. 
The co-culture spheroid invasion assay that I have used in chapter 3 demonstrated 
robust observations and would be a good base for the drug screening platform. The 
aim in this chapter is to further optimise the co-culture spheroid invasion assay with 
cell line models identified in the previous chapter, and develop it into a drug 
screening platform. The drug screen assay should be straightforward with little 
handling steps, which would increase reproducibility and reduce time and complexity 
of the screen. Furthermore, cellular morphology and phenotype in the spheroid 
invasion assay will be validated in vivo through intravital imaging of mouse xenografts. 
Moreover, performance of positive and negative controls will be validated against 
the standard of care in the drug screen assay. The analysis step should be quick and 
robust, preferably automated in order to allow high throughput drug screening. This 
drug screen platform could be used as a tool to identify novel migrastatics and 
cryostatics by assessing invasion and growth of the 3D co-culture spheroid in the 
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early phase of drug discovery studies. Promising hits should be further validated with 




 Defining the optimal spheroid formation conditions of Patu8988T and 
PaTu8902 
In the previous chapter, I have conducted co-culture spheroid invasion assays with 
the preferred cell line models PaTu8902 and PaTu8988T in the presence of PS-1 cells 
(Figure 3-13). Previously, the hanging drop method was tested on the lid of petri 
dishes (data not shown). However, this was not optimal for drug screening as 
spheroids had to be transferred into wells. Hence, spheroids were generated in 96 
wells ultra-low attachment U-bottom plates, containing one spheroid per well. 
PaTu8902 demonstrated good and robust tight spheroid formation, whereas 
PaTu8988T demonstrated a less compacted spheroid formation. In order to confirm 
the most optimal spheroid formation conditions for PaTu8988T, different total cell 
numbers (1k, 2k &5k), spheroid formation duration and addition of methylcellulose 
were assessed in the Patu8988T cell line (Figure 4-1). Different total cell numbers did 
not contribute to a tighter spheroid formation in PaTu8988T, but only increased the 
spheroid size (5k cells spheroids data not shown). Similarly, increasing the duration 
of spheroid formation in the wells also did not contribute to a tighter spheroid, while 
it increased the size of the spheroid. The spheroid structure was already assembled 
around day 3 and did not change overtime, while the size would increase when 
incubated longer.  
Next, 0.32% methylcellulose was added as a crowding agent to the cultures to 
improve spheroid formation. However, methylcellulose did not aid the PaTu8988T in 
forming tighter spheroids. Moreover, doubling the total cell number or increasing 
the spheroid formation duration in the presence of methylcellulose did not affect the 
compactness and shape of the spheroids. These results suggest that spheroid 
formation ability of Patu8988T is not affected by cell numbers, time or external 
interaction with the crowding agent or treated well surface.  
As methylcellulose did not make a significant difference in the spheroid formation of 
Patu8988T, and it would make it more difficult to remove from the well during 
medium removal and matrix addition, it was left out from the spheroid formation 
 99 
protocol. As PaTu8988T and PaTu8902 spheroids grown with or without PS-1 started 
to form the spheroid body on day 2 and have formed a stable spheroid from day 3 
onwards, it was decided that the spheroid formation duration should be no longer 
than 3 days (Figure 4-2). By controlling the spheroid formation duration, the size 
could be controlled to avoid the diameter to surpass 500 μm, where the 
development of necrotic areas in the centre of the spheroid occurs and could cause 
variability in the drug screen (223, 224). At day 3 the PaTu8988T spheroid has an 
average diameter of 400μm, while the diameter of the PaTu8902 spheroids measure 
around 200μm. 
 
It is interesting to note that the PS-1 cells did not improve or hinder the spheroid 
formation of PaTu8988T or PaTu8902 cells (Figure 4-2). Overall, PaTu8902 has shown 
to be the first choice of cell line model due to its robust and tight spheroid formation 
over PaTu8988T at day 3 of spheroid formation. Therefore, PaTu8988T would be 


















Figure 4-1. PaTu8988T and PS-1 co-culture spheroid formation optimisation. 
Phase contrast images of co-culture spheroid formation of Patu8988T + PS-1 (1:1 
ratio) with a total cell number of 1000 or 2000 cells per well, over the course of 7 
days in the presence or absence of 0.32% methylcellulose. Scale bar= 100μm. Data 
































































Figure 4-2. Spheroid formation of PaTu8902 and PaTu8988T with and without PS-1. 
Phase contrast images of PaTu8902 and PaTu8988T spheroids in the presence or 
absence of PS-1 stellate cells over 3 days. Scale bar= 100μm. Data shown is 
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 Defining the optimal invasion conditions  
After defining the spheroid formation conditions, the invasion conditions were 
optimised. In order to find the most suitable extracellular matrix for the invasion 
assay, medium was replaced with either rat tail collagen I or a growth factor reduced 
Matrigel matrix for the PaTu8902 + PS-1 co-culture spheroids. Initial efforts caused 
centrifugation necessary after matrix addition, to keep the spheroids in the middle 
of the well. However, this could affect the spheroids and the polymerisation step and 
the protocol was adapted to avoid centrifugation by simply gentle pipetting. The 
spheroids in collagen I retained their shape after matrix polymerisation, whereas the 
spheroids in matrigel started to deform after polymerisation of the Matrigel (Figure 
4-3). This deformation caused by the Matrigel would increase variability in the 
starting point of the spheroid and would not be suitable for the drug screen. 
Therefore, collagen I would be the more suitable invasion matrix. 
Next, the invasion duration of PaTu8902 and PaTu8988T co-culture spheroids with 
PS-1 were assessed in collagen I matrix with DMEM/F12 medium + 10% FBS as 
chemoattractant (Figure 4-4 & 4-5). PaTu8902 co-culture spheroids showed single 
cell dissemination from day 2 onwards. By day 4 and 5 the cells have invaded to the 
periphery of the well. Furthermore, collective invasion and growth of the spheroid 
body has been observed. The PaTu8902 has a good invasion window between day 
two and day 4. Taking an ending time point shorter than day 4 would reduce the 
invasion window and sensitivity for invasion inhibition. Conversely, having an ending 
time point over 4 days would reduce the invasiveness as many cells have reached the 
side and top of the well.  
The PaTu8988T spheroids showed invasion 1 day earlier compared to the PaTu8902 
spheroids, starting 1 day after invasion initiation in collagen I. Similar to PaTu8902, 
the PaTu8988T invasion peaks at day 4, with cells at day 5 reaching the rim and the 
top of the well. However, the spheroid body expansion is much larger compared to 
the PaTu8902, which could make it more complicated to get accurate measurements 
for invasion. Nevertheless, the invasion in both spheroid models should ideally be 
assessed up to 4 days after invasion initiation. Reducing the cell numbers could be a 
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potential method to increase the invasion duration when long term drug responses 


























Figure 4-3. PaTu8902 + PS-1 co-culture spheroid structure in different extracellular 
matrix. 
Phase contrast images of PaTu8902 and PS-1 co-culture spheroids in polymerised rat 
tail collagen I and growth factor reduced Matrigel at spheroid formation day 3 
(Invasion time point d0). Scale bar= 100μm. Data shown is representative over 3 











































Figure 4-4. Invasion of PaTu8902+PS1 co-culture spheroid in collagen I. 
Phase contrast images of PaTu8902 and PS-1 co-culture spheroid invasion in collagen 
















































Figure 4-5. Invasion of PaTu8902+PS1 co-culture spheroid in collagen I. 
Phase contrast images of PaTu8988T and PS-1 co-culture spheroids in collagen I 





















 Visualisation of PaTu8902 and PS-1 cells through fluorescent labelling 
As the optimal formation and invasion conditions have been identified, it was 
important to elucidate the best method to identify and analyse the different cellular 
compartments in the spheroid. In order to facilitate analysis and the identification of 
the PaTu8902 and the PS-1 cells in the well, fluorescent tagging was applied. 
PaTu8902 and PS-1 cells were stably transduced with Lifeact-GFP (PaTu8902-GFP) 
and Lifeact-mrfpruby (PS-1-mrfpruby) respectively (Figure 4-6). The localisation of 
each compartment was visible upon spheroid formation. As the PS-1-mrfpruby cells 
were observed to be located inside the spheroid in clusters, the spheroid shape and 
invasive behaviours remained identical post transduction, demonstrating single cell 
dissemination of the PaTu8902-GFP cells. Similar observations have been made for 
the fluorescent labelled PaTu8988T spheroids (data not shown). Intriguingly, the PS-
1-mrfpruby cells mainly stayed in the centre of the spheroid and only a rare few cells 
were observed invading (See Figure 4-6 insert). 
With the fluorescent labelled cells, it was important to validate the localisation and 
the behaviour of the spheroids when different PaTu8902-GFP:PS-1-mrfpruby ratios 
were applied with the same total cell number of 1000 cells per well (Figure 4-7). 
Spheroid size or shape did not alter upon changes in ratios of Patu8902-GFP and PS-
1-mrfpruby cells. As the PS-1-mrfpruby compartment in the centre of the spheroids 
increases with the increased amount of PS-1-mrfpruby ratio, the invasion remained 
largely similar between the different ratios. In order to keep sufficient cancer cells in 
the model, the 1:1 ratio was adapted for simplicity yet recapitulating similar 
phenotype as the 1:2 ratio with more PS-1-mrfpruby cells. 
While it was tempting to test adding the PS-1-mrfpruby cells in the collagen to mimic 
the in vivo conditions more closely, I contemplated that it might result in large 
variability in a screen setting due to difficulties in generating an equal homogenous 
collagen I mixture with cells. Furthermore, different levels of contraction of the 
matrix caused by the PS-1 cells would also add to screen and outcome variability. 
Thus, the co-culture spheroids were initially generated by co-culturing both cell types 
in the ultra-low attachment U-bottom wells. This method has resulted in the 
localisation of PS-1-mrfpruby cells in the centre. In order to test whether it was 
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possible to have the PS-1-mrfpruby cells localised on the outer side of the spheroid, 
the PS-1-mrfpruby cells were added a day after the spheroid was generated. Ps-1-
mrfpruby cells were still found localised in clusters inside the spheroid rather than 
localised on the outer side of the spheroid on day 3 of spheroid formation ((Figure 4-
8). This result suggests that PS-1-mrfpruby cells are likely to actively migrate into the 























Figure 4-6. Invasion of standard and fluorescent labelled PaTu8902/PS-1 co-culture 
spheroids. 
Phase contrast and merged images of phase contrast and fluorescent PaTu8902-GFP 
(Green) and PS-1-mrfpruby (Red) images, at the start of the invasion (day 0) and the 
end of invasion (day 4). Scale bar= 100μm.  
























































Figure 4-7. Spheroid formation and invasion of different PaTu8902-GFP and PS-1-
mrfpruby ratios. 
Merged phase contrast and fluorescent images of PaTu8902-GFP (Green) and PS-1 
mrfpruby (Red), in a monoculture spheroid (1:0) or in co-culture spheroid with 
different ratios of PaTu8902:PS-1 (1:1 and 1:2) at the beginning (day 0) and the end 



























Figure 4-8. PS-1 mrfpruby localisation in alternative spheroid generation method. 
Phase contrast, fluorescence and the merge images of PS-1 mrfpruby cells and 
PaTu8902 co-culture spheroids on day 3 of spheroid formation. PS-1 mrfpruby were 
added a day after spheroid formation was initiatied with PaTu8902-GFP only. Scale 
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 In vivo validation of PaTu8902 spheroid invasion characteristics 
The 3D spheroid model suitable for drug screening has now been established. While 
all the conditions have been optimised, it is important to demonstrate that the model 
is clinically relevant and resembles in vivo characteristics. To further validate the in 
vitro findings of the PaTu8902-GFP cell line model in vivo, I collaborated with Dr. 
Fernando Calvo and Dr. Nicola Ferrari at the ICR to image the cells in vivo in a mouse 
xenograft. The PaTu8902-GFP cells were injected subcutaneously into a nude mouse 
and intravital imaging was performed 20 days’ post injection. PaTu8902-GFP cells 
were forming small clusters/tumour bodies over time, similarly to the spheroid 
formation in vitro. Furthermore, the PaTu8902-GFP cells disseminated and invaded 
away as round and elongated single cells at the invasive front, whereas little 
migration was observed in the tumour body (centre of the tumours) (Figure 4-9). 
These results demonstrate that the PaTu8902 has the ability to form spheroid like 
tumours and invade in single cells in vivo, in a similar manner as shown in vitro with 
the spheroid assay. Future work is needed to quantify and confirm the numbers of 

































Figure 4-9. Invading PaTu8902-GFP cells in a nude mouse xenograft. 
Intravital imaging of PaTu8902-GFP cells (Green) and collagen (Magenta) at day 20 
post subcutaneous injection. Insert demonstrate the invasion of round and 
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 Semi- automated analysis for invasion quantification 
The fluorescent labelling has allowed the localisation of both cell types. Furthermore, 
the fluorescent signal could aid the quantification analysis of the invasion. To 
quantify the invasion in a more automated manner rather than measuring the 
distance of each invaded or the average furthest invaded cell per quadrant, the 
fluorescent signal was used to quantify the measurement by utilising a threshold 
(Figure 3-13 and 3-14). Fluorescent images were collected from the microscope and 
the images were processed in ImageJ. By using the fluorescent signal, the overall 
invasion area can be measured as a surrogate quantification for the invaded distance. 
The more invasion there is, the larger the area of the fluorescent signal is going to be. 
The area of the fluorescent signal is measured in ImageJ with the threshold setting 
to mask the fluorescent signal at the start and at the end of the invasion (Figure 4-
10). The measured area at the end of the invasion is then divided by the measured 
area at the start of the invasion to yield a relative invaded area. This is to account for 
any differences in the starting area. Once drug treatment is administered, the relative 
invaded area of the treated spheroids will be divided by the relative invaded area of 
the control treated spheroids to yield the relative inhibited area of invasion.  
It is important to note that this approach only allows values of >0, as there will always 
be a starting point signal of the non-invaded spheroid. Therefore, if 100% inhibition 
of invasion occurs or when the cells of the spheroid has undergone apoptosis, the 
relative value will still be >0. One could use a relative value of 1 for the treated 
spheroid area in the equation to obtain the final relative invasion value where 100% 
invasion inhibition has occurred without any growth of the spheroid itself, as an 
indication. Furthermore, this surrogate approach allows for sensitivity of the 
inhibition of the invasion only, or rather the reduction of measured invasion area, 
and will be not sensitive to identify invasion inducing compounds accurately. This is 
due to the saturation of the invasion of the cells and the expansion of the large GFP 
signal from the spheroid body. Images at an earlier time point or the spheroid 
invasion assay executed with a less invasive cell line could increase the sensitivity for 



















Figure 4-10. Semi-automated image analysis for measuring the invasion area. 
A threshold on the fluorescent signal is applied to the fluorescent images taken on 
the microscope and the area was measured in ImageJ. This is applied at the start and 
at the end of the invasion. The measured area is then normalised and the relative 
invasion was calculated comparing the treated spheroids against the control 
spheroids by using the formula as shown. tend= time point at end of invasion, tstart= 
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𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑖𝑛𝑣𝑎𝑠𝑖𝑜𝑛 =  
𝑑𝑟𝑢𝑔 𝑎𝑟𝑒𝑎 𝑡𝑒𝑛𝑑
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 Positive and negative controls for the spheroid invasion assay 
With the semi-automated quantification in place and having the formula to compare 
treated and control treated spheroid invasion, it was important to find and validate 
both positive and negative controls. DMSO was used as a negative control, whereas 
Dasatinib was tested to be as a positive control. Both compounds were compared 
with the standard of care: Gemcitabine (Figure 4-11). DMSO did not affect cell 
invasion in the co-culture spheroids and can be used as a negative control (Figure 4-
11B). As most 3D drug screens without matrix use a drug concentration between 
1μM and 50μM, 10μM was used as a starting point by taking into account the 
penetration difficulties from the matrix and the 3D spheroidal structure (224, 225). 
Spheroids treated with 10μM Gemcitabine showed a decrease of invasion with a 
relative invasion of 0.52. However, total inhibition of invasion was not observed as 
there were still several invading single cells and collective invasion of the spheroid 
body present. Next, Dasatinib was used to test inhibition of invasion, as it has been 
shown previously in mice and in vitro to block metastasis and invasion (122). 10 μM 
Dasatinib demonstrated total inhibition of invasion (relative invasion: 0.34), without 
any single cell dissemination or collective invasion from the spheroid body. 
Nevertheless, spheroid growth was still observed at this concentration. These results 
demonstrate that good drug penetration of the matrix was achieved and that 
Dasatinib and DSMO can be used as positive and negative controls for the spheroid 



































Figure 4-11. Spheroid invasion with controls and Gemcitabine. 
A) Merged images of PaTu8902-GFP and PS-1 mrfpruby co-culture spheroid invasion 
in the presence of negative control; DMSO, positive control; 10μM Dasatinib and 
standard of care; Gemcitabine at the start and the end of invasion (96hrs). Scale bar= 
100μm. B) Relative invasion quantified for spheroids treated with DMSO, 10μM 
Gemcitabine or Dasatinib. ±SEM, n=3. One-way ANOVA with Tukey’s multiple 
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Current available 3D pancreatic cancer drug testing models are based on spheroids 
generated from pancreatic cancer cell lines (213, 226). However, these models do 
not utilise stromal cells or extra cellular matrix. Only one study has demonstrated the 
use of fibroblasts with pancreatic cancer cells to form co-culture spheroids, but these 
fibroblasts (MRC5) were not pancreas specific (215). Moreover, these pancreatic 
cancer spheroid screens have cell proliferation or cytotoxicity as read out and does 
not investigate the invasive behaviours of pancreatic cancer cells. The co-culture 
spheroid invasion assay developed in this chapter is the first spheroid invasion assay 
optimised for pancreatic cancer modelling by introducing the PS-1 stellate cells into 
the culture. Here the aim was to further develop and optimise the platform to enable 
drug screening in a robust and simple manner for novel therapeutics against invasive 
pancreatic cancer cells.  
Several methods have been reported to generate spheroids from cancer cells. 
Hanging drop, ultra-low attachment coated u-bottom wells or the use of crowding 
agents such as methylcellulose were popular approaches for spheroid formation (212, 
213, 224). Hanging drop method would not be suitable for invasion screening due to 
the extra handling step of transferring spheroids. Methylcellulose was previously 
used to facilitate spheroid formation in pancreatic cancer (213). However, the 
authors have also reported that in certain cell lines such as MiaPaCa2 and ASPC1, 
methylcellulose addition did not facilitate compact spheroid formation. This finding 
is similar to the results in PaTu8988T, where the crowding agent did not improve the 
spheroid formation, suggesting that cell intrinsic factors such as contractility and 
cellular adhesion in PaTu8988T does not support the formation tight spheres. 
Generating spheroids in the ultra-low attachment coated u-bottom wells allows for 
single spheroid formation without the addition of any reagents. Furthermore, there 
is no need for spheroid handling when initiating the invasion assay compared to the 
other methods, making this method the most suitable for drug screening in invading 
spheroids.  
Strikingly, the localisation of PS-1 stellate cells in the co-culture spheroids is in the 
centre of the spheroid, despite the efforts of adding the stellate cells after a day of 
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spheroid formation to enhance homogeneous peripheral localisation. This is similar 
to what has been reported when cancer cells are co-cultured with stromal cells to 
form spheroids (215, 227, 228). Although, not every co-culture spheroid reported 
had fibroblasts in the centre. A study demonstrated a knock-out of Ext1 enzyme, 
which impaired invasion in fibroblasts and resulted in fibroblasts sitting on the 
outside of the spheroids (228). Whether the orientation of the co-culture spheroids 
is dependent on the invasiveness of the stromal cells remain unclear. Nevertheless, 
the orientation did not affect the invasion of cells in this study, but could potentially 
contribute to increased survival through reciprocal signalling (94). 
It has been shown that organoids, which are normally grown in Matrigel, did not 
demonstrate invasion in Matrigel (229, 230). Only if they were transferred into 
collagen I matrix, invasion was observed. Interestingly, when PaTu8902 + PS-1 co-
culture spheroids were embedded in Matrigel, the spheroid structure started to 
change. Difference in stiffness, density and matrix signalling could cause the change 
in shape, which could be a result of increased spreading, invasion or proliferation 
(231). Pure matrigel stock (8mg/ml) has a higher density and smaller pores compared 
to collagen I, which is usually used at concentrations around 1-2mg/ml (232). 
Nevertheless, invasion of PaTu8902 and PaTu8988T into the matrix containing 
collagen I has been published previously (193, 233).  
The in vitro spheroid formation and invasion resembled the findings in vivo, where 
cells invaded as single cells from tumour clusters towards the dense and rich collagen 
fibered area. It has been demonstrated that pancreatic cancer cells and cancer 
associated fibroblasts are able to remodel the surrounding extra cellular matrix and 
increase invasion through ROCK activity (234, 235). Furthermore, it has also been 
reported that patients with an increase in thick collagen I fibers in their tumours had 
a lower overall survival (184). Moreover, collagen I has been shown to increase 
motility and invasion of pancreatic cancer cells by inducing EMT through 
upregulation of Snail (236). It will be of future interest to include pancreatic stellate 
cells in the in vivo studies to identify their contribution and effect on the invasion of 
PaTu8902 cells. In addition, confirming findings of the role of actomyosin contractility 
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and ROCK activity in the invasion and remodelling of the extra cellular matrix in 
PaTu8902 would further validate our system and increase its clinical relevance. 
Recent findings of pancreatic stellate cells contributing to the invasion of pancreatic 
cancer cells reveal an important role for these stromal cells in the progression of the 
disease. In this study, only the cancer cells have been investigated and quantified 
with the developed analysis method. Due to the randomly nested PS-1 cells in the 
spheroid at the starting point of each invasion assay, it is difficult to have a robust 
and stable performing assay to investigate the PS-1 cells in this manner. It has been 
reported that stellate cells are able to contribute to the invasion of pancreatic cancer 
cells through FGFR signalling for example, and can be inhibited by the use of 
PD173074 (141). Future studies with FGFR inhibitor PD173074 in the co-culture 
spheroids would be of interest to investigate and validate contributions of PS-1 cells 
towards PaTu8902 cancer cell invasion.  
Another challenge remains regarding viability and cytotoxicity end point 
measurements in the invasion assay. While cell viability was being tested in various 
methods, I was not able to obtain a robust method for a stable and accurate read out 
of the in matrix embedded spheroid’s viability through reagents such as MTT, Alamar 
blue, cell titer glo and cell titer glo 3D. Due to the presence of the extra cellular matrix, 
reagents do not easily penetrate the matrix and the 3D spheroid architecture 
homogeneously. Degrading the collagen with collagenase combined with cell titer 
glo 3D or flow cytometry analysis of disseminated cells could provide a solution to 
the penetration issue of the currently available reagents. Future efforts in realizing 
this could increase the attractiveness of this 3D drug screening platform for high 
through put high content drug discovery. Overall, the 3D co-culture spheroid is a one 
plate assay for invasion and growth analysis, without needing to transfer spheroids 
over (Figure 4-12). Furthermore, the assay is designed to be adopted for automated 
high throughput drug screening.  
Gemcitabine and Dasatinib have demonstrated to penetrate the 3D matrix and the 
spheroid, resulting in partial or full inhibition of invasion respectively at the dose of 
10μM. However, the reported IC50 value for Gemcitabine in PaTu8902 cells on 2D 
plastic by the sanger institute is several times lower than the concentration we have 
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used here in the 3D spheroid invasion assay (0.29μM vs 10μM) 
(www.cancerrxgene.org). Conversely, Collisson et al have reported a much higher 
IC50 value for Gemcitabine for PaTu8902 (~100 μM) cultured in 2D with similar 
viability reagent (cell titer glo) and treatment duration (53). Nevertheless, the 
concentration used in the 3D spheroid invasion assays falls into this range and has 
demonstrated to inhibit invasion partially, with viable cells that have invaded. Future 
dose calculations should be made to compare the clinical dose with the used dose in 
this setting. Also, dose response curves could be generated against viability of the 
cells in 3D. 
Dasatinib has been demonstrated to inhibit invasion in vitro through src-inhibition 
and inhibited the development of metastasis in a genetic mouse model with KRAS 
and P53 mutations targeted in the pancreas (122). Similar findings were 
demonstrated with close to 100% invasion inhibition at 10μM in the 3D spheroid 
invasion model, whereas the authors have demonstrated an average of 60% 
inhibition of invasion in a transwell invasion model at a concentration of 100nM (122). 
However, Dasatinib seemed to have modest effect on cell viability in the 3D spheroid 
invasion assay as the spheroid still expanded despite inhibited invasion. Other 
studies demonstrated nanomolar to micromolar range IC50 values of Dasatinib on 
pancreatic cancer viability in 2D (122, 165). Nevertheless, the modest effect on 
proliferation by Dasatinib did not increase overall survival in pancreatic cancer or 
metastatic disease when used in combination with gemcitabine or alone respectively, 
probably due to primary tumour development and burden (237, 238). Further 
investigation is needed to confirm the lack of viability inhibition by Dasatinib in 3D 
spheroid invasion assay. Other combination therapy of Gemcitabine with Dasatinib 























Figure 4-12. Schematic overview of the 3D co-culture spheroid invasion platform. 
Cancer cells PaTu8902-GFP and stromal cells PS-1-mrfpruby are seeded into a 96 
wells U-bottom plate treated with ultra-low attachment coating. Spheroid formation 
occurs over 3 days and growth medium is exchanged for collagen I matrix. After 
polymerisation, growth medium containing 10% FBS is added on top of the matrix 
and treatments can be added into the medium. Fluorescence microscopy is used to 
acquire the images of spheroid invasion and semi-automated invasion quantification 
in ImageJ is applied to measure the invasion inhibition. 
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4.4. Future work 
This chapter was dedicated to developing a 3D assay platform for drug screening 
against invasion and cytotoxicity. While the assay has been optimised for drug 
discovery against invasion, the growth, cytotoxicity and the contribution of PS-1 
stellate cells read outs need more optimisation. Invasion conditions could be 
improved to increase the invasion of PS-1 cells to allow for screening stellate cell 
invasion inhibiting drugs. Furthermore, the analysis has to be tested with the ImageJ 
quantification method and might need modification to increase its sensitivity. 
Several live tracker dyes for cell death and hypoxia are available with a far-red 
fluorescent dye, which could be used to measure the changes in total cells per well. 
Moreover, collagenase could provide a good alternative to isolate the cells and 
prepare the samples for FACS/flow cytometry analysis. This allows the quantification 
of cell death and proliferation of the pancreatic cancer cells and the stellate cells.  
However, this method might reduce the high throughput capacity. Optimising the 
platform for high throughput or automated imaging and analysis machines would 
significantly increase the speed and the screening capacity. Validation with mono-
culture spheroids or 2.5D collagen assays could provide valuable information in the 
meantime. 
Alternatively, incorporation of other extra cellular matrix proteins could improve the 
validity and clinical relevance further. For example, Collagen IV and Hyaluronic acid 
have been shown to increase proliferation and invasion of pancreatic cancer (239, 
240). Future works with added stromal compartments such as endothelial cells or 
immune cells could mimic the in vivo behaviour and characteristics of pancreatic 
cancer even more closely, which could potentially increase its clinical relevance even 
further. 
Also, further validation of the in vivo model could provide us more insight into the 
contributions of PS-1 stellate cells by introducing them into the PaTu8902 and 
potentially also the PaTu8988T xenografts. Also, quantification of cell shape and 
collagen fibre thickness would provide valuable information regarding the invasion 
characteristics of the PaTu8902 and PaTu8988T cells. Moreover, future drug dose 
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response studies and clinical dose conversion could provide more insight into 
concentration translation from 2D to 3D in vitro, in vivo models and clinic. 
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 Results III: Drug repositioning screening in pancreatic cancer 
5.1 Introduction 
Until now, rarely any drug screens have been performed on pancreatic cancer, mainly 
due to the lack of a good understanding of the disease and a model, which translates 
into in vivo and the clinic. Recent efforts have led to the development of several in 
vitro models mimicking the disease more accurately (206, 226). In order to bridge the 
gap between a single compartment model and complex in vivo models, I have 
developed a multi-compartmental model consisting of cancer cells, stromal cells and 
3D matrix as described in the previous chapter.  
High throughput drug screening of novel compounds is costly and time consuming to 
follow up and still might not yield clinical efficacy. Drug repurposing or drug 
repositioning is an alternative on-target or off-target approach to drug discovery by 
identifying different drugs acting on a known target or by investigating the novel 
mechanism of a known drug through (241, 242). The major advantage of drug 
repurposing is that the pharmacokinetic, pharmacodynamics and toxicity profiles or 
most of the drugs are already known due to previously conducted preclinical and 
phase I studies (241). Therefore, these drugs can be launched into phase II and III 
more readily and thus save time and costs. The application of non-cancer drugs for 
cancer therapy has been based on the exploitation of the off-target effects in 
addition to their principal activity. If sufficient potency is observed with the off-target 
effect, the drug could be tested in patients faster (243). Furthermore, as common 
molecular pathways or targets can give rise to different diseases, drugs targeting 
these common mechanisms or targets could be applied for different diseases. This 
approach has led to the repurposing of drugs for cancer treatment such as 
thalidomide (244), celecoxib (245), methotrexate (246). 
Nevertheless, one of the criteria of drug repurposing is that the drug needs to have 
a valid mechanism of action applicable for the type of cancer to access their efficacy 
in the human body. Furthermore, cancer treatments with unknown side effects of 
repurposed drugs will need validation with new clinical studies (247). Moreover, 
several drugs such as digitoxin and doxycycline, demonstrated significant toxicity and 
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unwanted drug-drug interactions (248, 249). Also, different route of administration, 
dosing or drug formulation pose different toxicity profiles and efficacy that need 
further investigation (241). Therefore, it is important to assess the biological activity, 
the selectivity of the drug and pharmacological parameters of a potential repurposed 
drug prior to selection for further clinical investigation, to avoid failure in later stages.  
In order to accelerate the development of therapeutics against pancreatic cancer and 
the translation from bench to bedside, I have utilised an FDA approved library for 
drug repurposing screening in my 3D spheroid invasion assay. The aim of this chapter 
is to define the drug library, to perform the screen in the 3D spheroid invasion assay 
and to validate the screen results acquired by semi-automated analysis with manual 
scoring. Furthermore, top 5 hits will be taken forward for validation on the 2.5D 
Collagen I assay. The validated hits could then be taken forward for further validation 
in vivo.   
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5.2 Results 
5.2.1 Drug library assembly for drug repurposing screen 
Prior to performing the drug screen, I had to assemble a drug screen library 
containing FDA approved drugs for drug repurposing. Enzo Life science had the 
smallest FDA approved drug library available consisting of 800 drugs compared to 
libraries with 1000+ compounds provided by other companies. The lack of having an 
automated workflow in line restricted the number of compounds that I would be able 
to screen through the 3D spheroid invasion assay. Performing a high throughput drug 
screen was in this stage physically not possible given the time frame. Therefore, the 
drug library had to be narrowed down to a feasible size.  
Starting with 800 FDA approved drug compounds, I have first filtered out the 
duplicate compounds which where categorised in the same indication (e.g. Anti-
Inflammatory, anti-viral), as these usually have similar targets or mechanism of 
action (Figure 5-1). These duplicates were filtered by age as older compounds are 
usually less specific compared to newer compounds, which would make it harder to 
determine or validate the mechanism of action if the compound was found promising. 
This also accounts for drugs that have multiple targets, to be excluded in this filtering 
stage. However, some of the anti-neoplastics were kept in the library as potential 
controls, while duplicate kinase inhibitors were excluded from the library to allow 
space for unknown anti-neoplastic compounds. These filtering steps narrowed down 
the drug library to 99 compounds, making it feasible for the semi high throughput 
screening. Subsequently, 10 in-house compounds, either of specific interest (e.g. 
Rock inhibitors) or compounds obtained from pharma through an MTA were included 





































Figure 5-1. Drug compound library selection process 
Schematic representation of drug screen library compound selection. 800 
compounds from Enzo Life Science Screen Well FDA Approved compound library 
were first filtered down by excluding older compounds with the same drug indication 
and keeping the anti-neoplastic compounds yielding 261 compounds. Drugs with 
similar mechanism of action were then excluded and 10 in-house compounds of 
interest were added contributing to a final drug library of 109 compounds.  
800
• Enzo Life Science Screen Well FDA approved compound 
library
261
• Removed older duplicate drugs based on indication
• Keep anti-neoplastics
99
• Removed drugs with similar mechanism of action
109














5.2.2 3D spheroid invasion assay drug screen  
As defined in chapter 4.2.6, 10μM was used as screening concentration throughout 
the screen in order to overcome the difficulties of matrix and 3D structure 
penetration, to generate compounds with medium to strong invasion inhibition 
effects for follow up studies. In order to save time and cost, drug screens are often 
conducted in triplicates to screen out promising compounds for further validation. 
The same approach was adopted for this screening experiment due to time and cost 
restrictions. Each 96 wells screening plate contained triplicates of either DMSO and 
Dasatinib as negative and positive controls for invasion inhibition respectively. 
Gemcitabine was also included into every plate as an extra internal control and a less 
strong positive control. This provides space for 27 compounds to be screened per 
plate. In order to carry out the screen for all the drugs, 5 plates were used in total to 
complete the screen. To determine the effectiveness of the newly developed assay 
for drug screening and to confirm the quality of the results obtained from each 
screening plate, a Z’-factor was calculated (250).  The Z’-factor was calculated for all 
plates based on Dasatinib as positive control and DSMO as negative control, resulting 
in an average Z’-factor of 0.55 across all the screening plates; proving to be an 
excellent assay when the Z’-factor lies between 1 and 0.5 (250). Only one plate did 
not demonstrate an acceptable Z’-factor and was therefore discarded and repeated. 
Screen results were normalised to DMSO to obtain the relative invasion value to 
allow for cross plate comparison (Appendix 1: List of drugs). The semi-automated 
quantification method will, in most cases, not reach a value of 0 due to the presence 
of a GFP signal from the spheroid even in the presence of invasion inhibition. The 
exception would be where the drug has eradicated all the cells, which would be 
unlikely. Indeed, the screen results demonstrated a range of responses and values 
above 0, ranging from total inhibition of invasion similar as Dasatinib (e.g. 
Tranexamic acid, Nebivolol) to increased invasion (e.g. valsartan, caffeine) (Figure 5-
2, 5-3, 5-6 & Appendix: List of drugs). Furthermore, several compounds have shown 
to yield a lower relative inhibition value than the positive control Dasatinib (e.g. 
GSK2126458, Doxorubicin, Digoxin), suggesting that these compounds are inhibiting 
the growth of the spheroid or affect the viability of the spheroid (Figure 5-3 and 5-5). 
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As there is not direct growth and viability read out from the 3D spheroid invasion 
screen, further investigation is needed to determine the effects of these compounds 
on cell growth and viability. Overall, the screen has identified several compounds 
with a stronger inhibition of invasion effect compared to gemcitabine and 


















Figure 5-2. Drug repositioning screening including in-house compounds 
Drug screen results ranked hits from invasion inhibition to increased invasion. DMSO 
used as negative control, Dasatinib used as positive control and Gemcitabine as 
standard of care comparison. Data shown of average relative invasion triplicates ± 
S.E.M. Black line indicates relative invasion of 1 and red line indicates relative 
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Figure 5-3: 3D spheroid invasion drug screen results. 
Representative merged images of PaTu8902-GFP and PS-1-mrfpruby co-culture 
spheroid invasion in the presence of DMSO or 10μM drug compound treated for 







DMSO Dasatinib Gemcitabine 
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5.2.3 Drug screen results through manual scoring analysis 
As the results of the drug screen were defined by the GFP signal obtained from the 
fluorescent images of each well, the inhibition of invasion measurement was 
quantified through a surrogate parameter. The area of the GFP signal determines the 
area of invasion indirectly, which was described in chapter 4. In order to scrutinise 
the use of this surrogate parameter, I have manually scored each acquired image for 
invasion based on a scoring system (Table 5-1). Single cell dissemination and 
collective cell dissemination from the spheroid would be seen as events which are 
highly invasive in vitro and in vivo. Both parameters are therefore multiplied by a 
factor of 2 to emphasise this effect over the other two parameters. Collective cell 
invasion describes the break-away streams or sheet like migration of collective cells 
from the spheroid whereas the intactness of the spheroid body describes the 
observation of a well-defined spheroid body border or the loss of it. Both of the latter 
parameters describe early stages of invasion and are therefore not multiplied. The 
total score is then calculated by adding up the scores of each parameter and divided 
by the total score of the negative control, which yields a relative invasion score. The 
lower the score the higher the inhibition of invasion observed and the higher the 
score the lower the inhibition of invasion.  
The results of the manual invasion scoring demonstrated similar results as the 
relative invasion analysis by semi-automated quantification (Figure 5-4A). However, 
unlike the semi-automated analysis, the manual invasion scoring has the possibility 
to reach a relative invasion score of 0 when a drug demonstrates full inhibition of 
invasion (e.g. Dasatinib). Therefore, when a linear correlation comparison was 
performed, the line did not cross 0,0 (Figure 5-4B). Nevertheless, majority of the 
compounds which were identified as strong inhibitors of invasion by relative invasion 
were correlated with a relative invasive score of 0. As this was a comparison between 
two continuous variables, a Pearson correlation coefficient test (parametric) was 
performed. The Pearson coefficient demonstrated the presence of a strong 
correlation (between 0.5 and 1.0; Pearson r:0.72) between the scoring of both 
methods. Interestingly, several drug compounds demonstrated a better effect of 
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invasion inhibition compared to Gemcitabine on the relative invasion scale compared 
to the relative invasive score scale.  
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Table 5-1: Scoring parameters used for manual scoring of invasion 
Single cell dissemination (Score multiplicity of 2) 
Score Description 
0 no dissemination 
1 very little dissemination <15 cells 
2 little dissemination (within 2x spheroid diameter) 
3 moderate dissemination (within 2.5x spheroid diameter) 
4 high dissemination (>2.50x spheroid diameter) 
 
Spheroid body intact (Score multiplicity of 1) 
Score Description 
0 no spheroid border visible 
1 partially border visible 
2 intact (visible border and centre0 
 
Collective cell dissemination from spheroid (Score multiplicity of 2) 
Score Description 
0 no collective dissemination 
1 little dissemination 
2 moderate dissemination (invasion into more than 1 direction) 
3 majority collective invasion 
 
Collective cell invasion (Score multiplicity of 1) 
Score Description 
0 no collective invasion  
1 presence of collective group invasion (attached to the spheroid) 
2 half of population is collective group invasion 





































Figure 5-4. Drug screen results of invasion inhibition by manual scoring. 
A) Graph of ranked results of drug screen compounds based on relative invasive 
scoring. Black line indicates relative invasion of 1 and red line indicates relative 
invasion of Gemcitabine. Data shown of average relative invasive scoring triplicates. 
B) Correlation graph between relative invasion and relative invasive score. Each dot 
represents a compound. Red line indicates the linear relationship expressed through 
R squared. Grey solid lines indicate the DMSO values on both axis, whereas the grey 
dotted line indicate the Gemcitabine values on both axis. Pearson correlation 
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5.2.4 Top hits identification and comparison 
The drug screen and the follow up scoring has indicated several promising inhibitors 
of invasion (Figure 5-2 and 5-4). The top 12 compounds which demonstrated stronger 
inhibition of invasion than Gemcitabine were compared, as Gemcitabine was ranked 
#12 in the semi-automated analysis method. Similar drug compounds are found 
within the top 11 hits identified from both analysis methods (Figure 5-5 and Table 5-
2). 10 identical compounds were identified as top hits from both methods, including 
controls Dasatinib and Gemcitabine. Only Ursodiol and Leflunomide were identified 
through the semi-automated analysis, whereas ROCK inhibitors GSK269962a and 
H1152 were picked up from the manual invasive scoring method. Only two of the 
common hits identified by both methods, GSK2126458 and Foretinib, are kinase 
inhibitors. This result demonstrates that there are several compounds which are non-
kinase inhibitors that elicit strong inhibition of invasion in the drug screen.  
In order to select drug compounds for follow up validation, the non FDA approved 
in-house drug compounds were excluded as they would potentially take longer to 
reach clinic and patients. These include in-house drug compounds GSK2126458, 
Doxorubicin and Foretinib, and will be investigated in future experiments separately. 
The remaining FDA approved drug compounds were filtered based on whether they 
are or have been tested before in clinical trials against pancreatic cancer. Vorinostat, 
a histone deacetylase (HDAC) inhibitor, has been found in clinical trials against 
pancreatic cancer. A couple of clinical trials for Vorinostat have been terminated due 
to lack of patient sample size, while several other phase I studies have been actively 
recruiting, or have been completed, but without results yet (https://clinicaltrials.gov/; 
NCT00831493, NCT00983268, NCT02349867, NCT00948688). Vorinostat is therefore 
excluded. The remaining compounds; Digoxin, Tranexamic acid, Nebivolol, 
Leflunomide and Ursodiol have not been taken to clinical trials yet for pancreatic 
cancer.  
Nebivolol, Tranexamic acid and Digoxin treated spheroids demonstrated comparable 
inhibition of dissemination of cells and maintained a similar size of spheroid 
compared to Dasatinib (Figure 5-6). However, spheroids treated with Nebivolol and 
Tranexamic acid demonstrated a more irregular border shape, with cells trying to 
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invade and disseminate, whereas Digoxin treated spheroid had a well-defined border 
and did not show any sign of invasion. Leflunomide and Ursodiol were not able to 
block invasion to the extent of Nebivolol, Tranexamic acid and Digoxin (Figure 5-6). 
Nevertheless, both compounds demonstrated similar inhibition of invasion as 
Gemcitabine, reducing the amount of disseminated cells, but had minimal effects on 
spheroid body expansion or collective invasion. Further investigation is needed to 
validate these observations and define the mechanism of the drugs in the inhibition 
of cellular dissemination or viability. These compounds were therefore taken forward 
as the top 5 compounds for further validation, as all the compounds demonstrated 
stronger inhibition of invasion compared to Gemcitabine. The in-house drug 
compounds GSK269962a and H1152 are ROCK inhibitors and will be discussed later 







































Figure 5-5. Top hits of drug screen by semi-automated analysis and manual invasive 
scoring. 
A) Top 13 hits from drug screen based on relative invasion and B) relative invasive 
scoring. Red line indicates relative levels of Gemcitabine. 
Relative Invasive scoring 





















































































































































































Table 5-2: Ranking of top 13 drugs by either relative invasive or relative invasive score. 
Rank by: 
# 
Invasion Invasive Scoring 
1 GSK2126458 Dasatinib 
2 Doxorubicin Doxorubicin 
3 Digoxin Foretinib 
4 Vorinostat GSK2126458 
5 Foretinib Tranexamic Acid 
6 Tranexamic Acid Vorinostat 
7 Dasatinib Digoxin 
8 Nebivolol Nebivolol 
9 Leflunomide Gemcitabine 
10 Ursodiol  GSK269962 
11 Gemcitabine H1152  
Positive control Dasatinib and Gemcitabine are highlighted in bold. In-house drug 
compounds are highlighted in cursive. FDA-approved compounds found in clinical 































Figure 5-6: 3D Spheroid invasion drug screen top 5 results. 
Representative merged images of PaTu8902-GFP and PS-1-mrfpruby co-culture 
spheroid invasion in the presence of DMSO or 10μM drug compound treated for 
96hrs. Scale bar= 100μm.  
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DMSO Dasatinib Gemcitabine 
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5.2.5 Viability effect of top 5 promising hits 
In order to investigate whether the top 5 drug compounds selected from the drug 
screen would have an effect on cell viability in addition to or instead of invasion, the 
compounds were tested in a viability assay. While performing the viability assay in 
the 3D spheroid invasion assay would be ideal, more experiments and optimisation 
is needed to obtain robust and accurate results from this set-up due to the challenges 
of homogenous penetration of the reagents all the way deep into the spheroid core. 
By taking a step backwards and performing the viability assay on cells grown in the 
2.5D collagen I assay rather than 2D plastic, I hope to gain a better insight into the 
viability effects of these compounds in 3D. 
PaTu8902 cells were grown on the 2.5D collagen I matrix and drugs were 
administered at different concentrations (Figure 5-7). Viability was measured 72 hrs 
post-treatment as viability effects were observed in cells treated with Gemcitabine 
(Figure 5-5 A&B). 72hrs treatment with 20 μM Gemcitabine demonstrated round up 
and detached cells from the collagen (Figure 5-7 A). Similar observations were made 
with Nebivolol. Majority of the cells treated with 20 μM Digoxin or Leflunomide 
detached from the collagen matrix and remained floating in the medium. Cells 
treated with 20 μM Tranexamic acid or Ursodiol did not demonstrate differences in 
morphology and confluency compared to DMSO. Indeed, both Tranexamic acid and 
Ursodiol did not affect viability even at 20 μM (Figure 5-7 B). While Nebivolol and 
Digoxin demonstrated strong impairment of viability, Leflunomide demonstrated 
partial viability inhibition at 20 μM. At the screening concentration of 10 μM in 3D, 
drug compounds Nebivolol, Tranexamic acid, Ursodiol and Leflunomide did not 
demonstrate effects on cell viability. Only Digoxin demonstrated strong effects on 
cellular viability even at lower concentrations up to 500nM. These results suggest 
that several drug compounds inhibited invasion without affecting viability and drug 
compounds like Digoxin which inhibited invasion and affected viability. Whether the 
viability reduction partially or fully contributed to the invasion inhibition is unclear. 
Future experiments are needed to further validate these compounds abilities to 






































Figure 5-7. Viability validation of top hits from drug screen. 
A) Representative phase contrast images of PaTu8902 cells on 2.5D collagen I matrix 
treated with DMSO or 20μM drug compound at 72hrs. B) Graph of relative viability 
of PaTu8902 cells on 2.5D collagen I matrix treated with drug compounds at different 
concentrations for 72hrs compared to DMSO. A final concentration of 44 uM Alamar 
Blue was added to the cells at the end of 72hrs to measure viability.  
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5.2.6 ROCK inhibitors partially inhibit invasion in 3D spheroid invasion assay 
In the third chapter, it was discussed that contractility played an important role in 
the formation and behaviour of these pancreatic cancer cells. PaTu8902 and 
PaTu8988T both demonstrated presence of contractility. It was therefore of interest 
to observe whether ROCK inhibitors would perform well in the drug screen by 
reducing the contractility in the cells thus reducing their invasiveness. Indeed, drug 
screen results and follow up results demonstrated that PaTu8902 spheroids treated 
with 10μM GSK269962a or H1152 demonstrated reduced invasion and were placed 
in the top 12 drug compounds hits by manual scoring (Figure 5-8 & Table 5-2). A 
strong reduction was found in the cell dissemination events, yet the spheroid 
demonstrated expansion, indicating a lack of inhibition of proliferation, collective 
invasion or expansion of cell area/size due to loss of contractility. This therefore 
explains the lower ranks for both compounds analysed through the semi-automated 
method, which quantifies the GFP area. Further validation is prompted in different 
cell lines such as the PaTu8988T and to investigate the effects of these ROCK 


































Figure 5-8. Rock inhibitors inhibiting invasion in PaTu8902 + PS-1 co-culture 
spheroids. 
A) Representative merged images of PaTu8902-GFP and PS-1 mrfpruby co-culture 
spheroid invasion in the presence of 10μM GSK269962a or H1152 treated for 96hrs. 
Scale bar= 100μm. B) Relative invasion quantified for spheroids treated with DMSO, 
10μM GSK269962a or H1152. ±SEM, n=3. One-way ANOVA with Tukey’s multiple 























































The aim of this chapter was to perform a semi-high throughput drug screen with the 
assembled FDA approved drug library in the previously developed 3D spheroid 
invasion assay. As mentioned previously, very little work has been invested in the 
search for compounds blocking invasion in pancreatic cancer. Here, I have identified 
top 5 drug candidates which elicited stronger inhibition of invasion compared to 
Gemcitabine through the semi-automated analysis method.  
In chapter 4 I discussed how this method would be able to pick up strong inhibition 
of invasion, but would not be sensitive enough to distinguish invasion inducing drug 
compounds with confidence. Nevertheless, Caffeine and Valsartan were initially 
identified as invasion inducers in this screening setting. Conversely, Caffeine has 
been reported to reduce migration and invasion in glioblastoma (251, 252). 
Interestingly, Caffeine has also been reported to upregulate pMLC through ROCK 
activity (251). Furthermore, Valsartan has also been shown to inhibit proliferation 
and invasion in nasopharyngeal carcinoma (253). Yet, these studies pre-treated their 
cells before assessing their invasive abilities. More work is needed to determine the 
effects of Caffeine and Valsartan on PaTu8902 3D spheroid invasion and validate 
whether this effect is cell or cancer type specific. Moreover, investigating the 
increase of invasion by drug treatment can be done by pre-treatment and looking at 
earlier time points. Drugs that increase invasion could uncover new insights into how 
cancer cells become invasive or become more invasive, so that therapies can be 
developed to target these mechanisms.  
The top 5 identified drug candidates demonstrated promising results. Digoxin, a 
natural cardiac glycoside extracted from foxglove, is known to inhibit NA+/K+ atpase 
pumps and is used in the clinic to treat heart failure or atrial arrhythmia. Furthermore, 
it has been reported to induce caspase-dependent apoptosis in pancreatic cancer 
cells and inhibit primary tumor growth and metastasis in an orthotopical mouse 
model for breast cancer (254, 255). However, concentrations used in the drug screen 
are almost 5 times higher than the reported toxicity concentration of over 2μM (256). 
Therefore, future experiments are needed to determine the lowest concentration 
possible with observed inhibition of invasion and without toxicity effects on the heart.  
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Nebivolol emerged from the drug screen as one of the potent inhibitors of invasion. 
Nebivolol is a third generation selective β1 adrenoceptor blocker used in the clinic to 
treat hypertension. Several studies have suggested the implications of β-blockers as 
cancer therapy (257-259). Nebivolol has been demonstrated to potentiate drugs that 
block proliferation in neuroblastoma tumours in mice (260, 261). This was 
irrespective of the selectivity of the β-blockers for adrenergic receptors, suggesting 
that it may act through another mechanism to elicit these properties. In the viability 
assay (Figure 5-7), Nebivolol did not demonstrate anti proliferative effects up to 
10μM, but has shown strong impact on cell viability at 20μM. Other β-blockers have 
been shown to potentiate the anti-proliferative effects of gemcitabine in pancreatic 
cancer (262). Future combination studies could validate the potentiation of anti-
proliferative effects of Gemcitabine in pancreatic cancer with lower concentrations 
of Nebivolol. Another study has shown that Nebivolol was able to suppress NOX 
activity, which are mediators of ROS, cell signalling and inflammation. NOX activation 
has been described in various cancer and is related to cancer progression, invasion 
and invadopodia formation (263-266). Similarly, Nebivolol demonstrated strong 
inhibition of invasion with almost no dissemination of cells in the drug screen. These 
findings suggest that Nebivolol could be a potential pancreatic cancer therapy and 
should be further investigated as a therapy against invadopodia invasion(265). 
Another promising drug compound that emerged from the drug screen is Tranexamic 
acid. Tranexamic acid is an anti-fibrinolytic and has been widely used in the clinic to 
stop excessive bleeding during surgery by competitively inhibiting the activation of 
plasminogen to plasmin, which normally prevents clotting by degrading fibrin (267). 
It is a well-tolerated drug with various administration routs; systemically, 
intravenously or orally (268). The general used dose is 10mg/kg, yet doses of 10x 
higher has also been reported for the management of post-surgical bleeding (269). 
The concentration used in the drug screen for Tranexamic acid falls into the range of 
the clinical concentrations and could be a potential therapy for blocking pancreatic 
cancer invasion.  
Excitingly, Tranexamic acid has been reported to inhibit invasion but not cell viability 
in tongue squamous cell carcinoma in vitro (270). This result was also observed in the 
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drug screen (Figure 5-6) and the viability validation (Figure 5-7). Previously, it has 
been shown that treatment with Tranexamic acid decreased lung carcinoma 
xenograft metastasis, and administration with urokinase increased metastasis (271). 
This was thought to be due to the formation of fibrinogen around the tumour cells 
trapping cancer cells and prevent them from metastasising (272). However, later it 
has been discovered that Tranexamic acid is able to bind to the 5 lysine binding sites 
on plasminogen, preventing its activation by urokinase type or (uPA) tissue type 
plasminogen activator (tPA) enzymes into plasmin (273, 274). Plasmin has been 
reported to activate pro-matrix metalloproteinases (MMPs), and increased activity 
in the plasminogen activation cascade has been associated with fibrosis, cancer 
progression and poorer prognosis (275-278). In line with these reported results, the 
metastatic cell line Patu8902 used in the drug screen has been known to express and 
secrete high levels of urokinase, which might explain the effective inhibition of 
invasion by Tranexamic acid. Moreover, it has been reported that the urokinase 
receptor; urokinase plasminogen activator receptor (uPAR), was overexpressed in 
neoplastic cells in majority of the patients and was correlated with a poor survival 
(279, 280). These findings suggest that further studies should be done on the 
potential of Tranexamic acid as a potential therapeutic to be used in combination 
with a cytostatic drug such as gemcitabine. In addition, urokinase and its receptor 
uPAR could be a potential target against pancreatic cancer invasion. 
The other two compounds of the top 5 drug candidates, Ursodiol and Leflunomide 
demonstrated higher invasive score than Gemcitabine. This is most probably due to 
the fact that certain drugs reduce invasion, resulting in a smaller “GFP area”. 
However, they may still present moderate single cell dissemination, which leads to a 
higher invasive scoring by the manual scoring method. Ursodiol is a synthetic 
secondary bile acid used for treating cholestatic liver diseases (281). Inconsistent 
outcomes have been reported regarding the role of Ursodiol in decreasing or 
increasing colorectal cancer (282). However, a recent abstract publication has 
reported that Ursodiol suppressed intracellular levels of ROS, decreased expression 
of EMT markers and stem cell formation in pancreatic cancer cells in vitro. As not 
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much has been reported regarding Ursodiol and pancreatic cancer, further 
investigation is needed to determine its mechanism and effect on cancer progression. 
Leflunomide is an antagonist of dihydroorotate dehydrogenase, which has been 
associated with mitochondrial electron transport and is required for de novo 
pyrimidine synthesis (283). It has been used for treating rheumatoid arthritis. 
Although viability was not affected by lefluonomide, the drug has been reported to 
inhibit the growth of human prostate cancer in vitro and in vivo (284, 285). However, 
another study demonstrated that leflunomide did not inhibit invasion in breast 
cancer (286). No studies have been conducted of leflunomide in pancreatic cancer 
and future experiments could further validate and determine the potentials of 
leflunomide as an inhibitor of pancreatic cancer invasion. 
Overall, this chapter has demonstrated the limitations and potentials of the 3D 
spheroid invasion assay as a drug screening platform. Several promising drugs hits 
have emerged with the ability of affecting cell viability of the highly invasive cell line 
Patu8902 and also drugs with strong inhibition of invasion without affecting cell 
viability. These drug candidates should ultimately be further validated and perhaps 
tested in combination with Gemcitabine and other drugs. Moreover, the drug screen 
was also able to validate compounds which were hypothesised to do well against 
pancreatic cancer, such as the ROCK inhibitors GSK269962a and H1152. Future 
automation and optimisation could potentially accelerate the discovery and 
development of novel therapeutics against pancreatic cancer.  
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5.4 Future work 
It is of importance to validate the screen hits further based on invasion effects and 
viability effects. The 3D spheroid invasion screen was able to provide insights on the 
effects of the drug compounds on a 3D cell structure confined in a 3D matrix, bringing 
in the aspect of barrier and internal concentration gradients. By utilising other forms 
of assays, such as the organotypic assay or 3D transwell invasion assay, the drug 
compounds can be further validated in 3D for invasion effects. This should also be 
done on other cell lines to see whether certain drugs elicit effects specific for the 
PaTu8902 cells, but might not have an identical impact on other cell lines with 
different genetic backgrounds. Nevertheless, this assay could be used to screen drugs 
that could work for a specific type of cancer with a specific genetic signature or 
background, making this assay an attractive tool for working towards personalised 
medicine. The only requirement is that cell lines or primary cells should be able to 
form consistent spheroids to yield meaningful and comparable results.  
 
An IC50 value should be determined from the invasion and the viability studies in 
order to compare the potential dose with the toxicity dose reported for these drugs. 
Furthermore, the mechanism of action should be confirmed whether it is acting 
through the documented selective target or whether the drug is eliciting inhibition 
of invasion through other targets. Once the drug has been confirmed to be acting on 
other targets than its indicated target, mechanistic studies should be conducted. This 
could include but not limited to: microarray, phosphoproteomics and metabolomics 
to pinpoint the target and the affected signalling pathway or pathways. 
 
Further validation of these hits should be done in vivo either in a xenograft model as 
demonstrated previously in chapter 4, which worked with success. An alternative is 
to have either a genetic engineered mouse model or an orthotopic xenograft model 
to validate the drugs further.  
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 Concluding remarks 
With limited amount of therapies available for pancreatic cancer, more focus is 
needed on the discovery of novel therapeutics against this malignant disease. Recent 
findings have demonstrated a crucial role for the tumour microenvironment in 
pancreatic cancer growth, invasion and survival (150). However, the lack of 
pancreatic cancer models in vitro that recapitulate in vivo behaviour, which are also 
suitable for drug screening against pancreatic cancer invasion remained a key hurdle. 
Previously, several efforts have tried to overcome this challenge by developing an 
organotypic assay for pancreatic cancer (203). Nevertheless, drug screening in 
organotypic assays are not cost effective despite their unique resemblance with 
desmoplasia in vivo. More recent work done on organoids provides researchers a 
tool to investigate key genetic drivers and the development of pancreatic cancer 
(204-206). Yet, these organoid assays are not cost effective and do not allow for drug 
screening against pancreatic cancer cell invasion. Since pancreatic cancer is a highly 
metastatic disease, this study aimed to develop a novel in vitro pancreatic cancer 
model suitable for drug screening against invasion, which accounts for components 
found in the tumour microenvironment such as extra cellular matrix and pancreatic 
stellate cells.  
First, a suitable cell line model for the drug screen assay was identified from several 
pancreatic cancer cell lines through the characterisation of the morphology and the 
phenotypical behaviour of pancreatic cancer. Similar to several highly invasive 
cancers such as melanoma and hepatocellular carcinoma, I have demonstrated that 
individual pancreatic cancer cells are able to adopt the highly invasive amoeboid 
morphology rather than only the suggested mesenchymal morphology (113, 183, 
287). This type of cellular behaviour was linked with the more invasive QM subtype 
as demonstrated by the increased levels of the contractility marker pMLC2, bleb or 
protrusion formation, and the enrichment of contractile genes. Furthermore, cells of 
QM subtype have a better spheroid formation ability, reflecting their in vivo tumour 
formation ability. Moreover, QM cells were more likely to adapt the individual cell 
phenotype on 2.5D collagen I matrix, and invade in an individual manner. The QM 
cell line PaTu8902 demonstrated all aforementioned phenotypical traits, had a 
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robust spheroid formation ability and as the most invasive cell line, it was thus 
chosen as the representative cell line model. During the in vivo validation, it was 
shown that injected Patu8902 cells were able to form tumours in vivo and 
disseminate from the tumour body in single cells with round and elongated 
morphologies (Figure 4-9), recapitulating the observations made in vitro (Figure 3-8, 
3-10, 3-11 & 4-4). These findings demonstrate for the first time that pancreatic 
cancer cells have the ability to adapt an amoeboid phenotype during invasion in vitro 
and in vivo. 
Secondly, the initial 3D co-culture spheroid invasion assay was further developed in 
this study and adapted for drug screening purposes. This assay demonstrated robust 
formation and invasion of co-culture spheroids consisting of Patu8902 cancer cells 
and PS-1 stromal cells, each tagged with LifeAct-GFP and LifeAct-mrfpruby 
respectively allowing semi-automated analysis of each compartment. No co-culture 
spheroids have been designed previously for pancreatic cancer with pancreatic 
cancer specific stromal cells; the pancreatic stellate cells. Only one study reported 
the use of MRC5 lung fibroblasts or pancreatic mesenchymal cell line LT2 to form co-
culture spheroids with pancreatic cancer cells (215). Although, several spheroid 
invasion assays have recently been developed for other cancers such as breast cancer 
and prostate cancer, no spheroid assays have been developed to conduct drug 
screening against pancreatic cancer invasion (212, 288). The observations made in 
vitro from the 3D spheroid invasion assay has been validated and recapitulate in vivo 
findings in the xenograft mouse model. This means that potential drugs from the 
drug screen can be validated in the in vivo xenograft model. Furthermore, the screen 
allows for semi-automated analysis and can be further optimised for full automated 
high throughput drug screening.  
The drug screening platform demonstrated robust results with Dasatinib and 
Gemcitabine as positive controls and DMSO as negative control. Dasatinib 
demonstrated strong inhibition of invasion as reported previously in vitro and in vivo, 
but did not inhibit cell viability in the assay nor improve patient overall survival in 
pancreatic cancer during clinical trials as reported previously (122, 237). However, in 
this study, results were obtained from effects on invasion but not viability. Viability 
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and proliferation could affect invasion of cells through the generation of 
chemogradient by nutrition competition (289). Furthermore, proliferation, survival 
and motility pathways overlaps and secreted growth factors are able to act on both, 
thus cell growth would affect cell motility (290). It is therefore crucial to be able to 
test viability and proliferation in the treated spheroids along with invasion. However, 
just like other 3D models, validation of viability of cells in 3D in matrix deemed a 
significant challenge to achieve robust results. Future efforts focussed on tackling 
viability and proliferation read out of 3D tumour spheroids in 3D matrix in vitro or in 
vivo will be extremely beneficial to this assay. 
Another limitation of the drug screen assay design is that it is not applicable for RNAi 
screening or validation experiments. Cells have to form relatable spheroids and 
therefore caution is needed when proceeding with experiments involving knock out 
or RNAi silencing methods to compare against the mock cells, as this can affect 
spheroid formation ability. Information regarding spheroid formation can be 
obtained in this method, yet if spheroids are not comparable at the start of the 
invasion assay, it will be difficult to make sense of the results at the end of the 
invasion. Furthermore, as the drug screen assay was optimised to pick up drug 
compounds that inhibit invasion, the drug screen is therefore less sensitive and 
robust for uncovering drugs which increase invasion. Adjustments could be made 
regarding the duration of the invasion part and a positive control increasing invasion 
is needed. Overall, the drug screen was designed to identify drugs against pancreatic 
cancer and more specifically pancreatic cancer invasion. This also implicates that if 
isolated primary cells are able to form a spheroid, personalised drug screening can 
be conducted.  
Lastly, after developing and optimising the drug screening platform for drug 
screening against pancreatic cancer, an FDA approved drug library was assembled 
and drugs were screened in the 3D spheroid invasion assay platform. The drug screen 
demonstrated robustness over the drug screen and the results yielded a range of 
effects on invasion, with 5 unique hits that have unknown anti-neoplastic effects and 
are currently or have not been in clinical trials previously. Follow up validation 
demonstrated that one of the 5 hits, Digoxin, demonstrated strong inhibition of 
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invasion and coupled with effects on viability. The other 4 hits, Tranexamic acid, 
Nebivolol, Ursodiol and Leflunomide demonstrated no effect on viability at screen 
concentration, but showed good inhibition of invasion. These results indicate that 
the drug screen was able to identify compounds which are able to target and affect 
the viability of these highly invasive and drug resistant cells. Furthermore, the drug 
screen also identified compounds which solely act on cell extrinsic effects, hence not 
affecting cellular viability but rather hinder the cells from invading into the 
surroundings through inhibiting secreted ECM modulating factors such as MMPs. 
Alternatively, these compounds demonstrate a difference in therapeutic window for 
effects on invasion and for viability. Together, these findings demonstrated a robust 
and effective drug screen assay platform, yielding several promising compounds for 
further validation. Future drug combination studies could also be conducted to mimic 
treatment in the clinic more closely. 
In this study, the 2.5D collagen I matrix assay was applied to characterise pancreatic 
cancer cell lines and demonstrated synergies between observations made in 3D in 
vitro and in vivo. This suggests that the 2.5D collagen I matrix assay could be adopted 
for characterisation and optimisation studies prior to moving onto 3D in vitro or in 
vivo studies. It was demonstrated that individual QM pancreatic cancer cells adopted 
an amoeboid phenotype, elicit increased contractility and demonstrated high 
invasiveness in 3D in vitro and in vivo. These results suggested that the ROCK pathway, 
which modulates cellular contractility, could be a potential therapeutic target against 
pancreatic cancer invasion. Results of the ROCK inhibitors GSK269692a and H1152 
from the drug screen and follow up studies demonstrated significant inhibition of 
invasion, indicating that ROCK inhibitors could be a promising treatment for 
pancreatic cancer. Recent studies in mouse models demonstrated that ROCK 
activation and increased pMLC2 levels increased extracellular modelling and 
increased growth and invasion of pancreatic cancer (184, 235). Another study has 
shown that treatment with the ROCK inhibitor Fasudil resulted in the remodelling of 
the extracellular matrix and enhanced the response of the pancreatic cancers to 
standard of care therapies (234). These studies emphasised ROCK inhibition as a 
promising therapeutic against pancreatic cancer. However, these studies suggest a 
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role of ROCK on extracellular matrix remodelling whereas results from this work 
suggests that ROCK inhibitors could also directly act on the pancreatic cancer cells 
and inhibit them from increasing contractility and adopting the invasive amoeboid 
phenotype. Further validation studies of inhibition of invasion in different cell line 
models, in vivo and effects on viability are needed to determine the potentials of 
ROCK inhibitors in pancreatic cancer. Furthermore, it will be of interest to 
demonstrate whether ROCK inhibitors are able to reduce the numbers of amoeboid 
and mesenchymal invading cells in the 3D spheroid invasion assay and the in vivo 
mouse model studies.  
Overall, this study has laid the basis of the existence of the amoeboid phenotype in 
pancreatic cancer, which could serve as a potential target by inhibiting ROCK and 
actomyosin contractility pathways. Furthermore, the study has developed a 3D co-
culture spheroid invasion assay and protocols for a semi-automated quantification 
method that was optimised for drug screening. This drug screen tool proved to 
recapitulate in vivo findings and was successful in identifying novel promising hits 
against pancreatic cancer and pancreatic cancer invasion. With further 
improvements, this cost-effective drug screen tool could accelerate the process 
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 Appendix: List of drugs 
 
Rank Name Drug class 
1 GSK2126458 PI3K (p110) and mTOR inhibitor 
2 Doxorubicin Topo isomerase 2 inhibitor 
3 Digoxin Sodium potassium adenosine 
triphosphatase inhibitor  
4 Vorinostat HDAC inhibitor 
5 Foretinib c-MET and VEGFR inhibitor 
6 Tranexamic Acid Plasminogen/plasmin inhibitor 
7 Dasatinib Src and BCR/ABL inhibitor  
8 Nebivolol·HCl β1 receptor inhibitor 
9 Leflunomide Dihydroorotate dehydrogenase inhibitor 
10 Gemcitabine·HCl Deoxycytidine analog  
11 Ursodiol Bile; reduces cholersterol absorption 
12 Tolterodine Tartrate Antagonist M2 and M3 muscarinic receptor 
13 Valganciclovir·HCl  Inhibitor of deoxyguanosine triphosphate 
14 Cinacalcet·HCl Calcimimetic 
15 Sitagliptin Phosphate Dipeptidyl-peptidase inhibitor  
16 Maraviroc CCR5 antagonist 
17 Ambrisentan Endothelin receptor antagonist 
18 Artemether Inhibition of PfATP6 and anti-oxidant 
enzymes 
19 Metformin·HCl Enhance release of glucagon-like peptide 1 
20 H1152 Rock inhibitor 
21 Alosetron·HCl 5-HT3 antagonist 
22 Mannitol Osmotic diuretic, Sweetener 
23 Doripenem Inhibitor of penicillin-binding proteins 
24 Leucovorin Calcium 
Pentahydrate 
Folic acid 
25 Paclitaxel (Taxol) Arrests cells in G2/M phase of cell cycle 
26 Miglitol  Inhibition of membrane bound intestinal a-
glucoside hydrolase enzymes  
27 Erlotinib EGFR inhibitor 
28 Febuxostat Inhibitor of xanthine oxidase 
29 GSK269962 Rock inhibitor 
30 Ramelteon MT1 and MT2 agonist 
31 Lenalidomide Upregulation of p21, T-cell activation, 
reduce VEGF, TNF-a and IL-6 
32 Pitavastatin Calcium HMG-CoA reductase inhibitor 
33 Tazarotene Agonist of retinoic acid receptor 
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34 Levocarnitine Carrier molecule in the transport of long-
chain fatty acids 
35 Levothyroxine·Na Agonist for thyroid hormone receptor 
alpha and beta  
36 Loteprednol Etabonate Inhibitor of Type II glucocorticoid receptor 
37 Carglumic Acid Allosteric activator of CPS1 




Inhibitor of H1 receptors 
40 Pazopanib·HCl RTK inhibitor of VEGFR1/2/3, PDGFRa/b 
and c-kit 
41 Bimatoprost Agonist of prostaglandin FP receptors  
42 Finasteride Inhibitor of Type II 5a reductase 
43 Nicotine Agonist of nAChRs 
44 Eplerenone  Antagonist of mineralcorticoid receptor 
45 Everolimus mTOR inhibitor 
46 Fingolimod Inhibitor of sphingosine 1-phosphate 
receptors 
47 Dobutamine·HCl Agonist of beta-1 receptors  
48 Milnacipran·HCl Inhibitor of NET and SERT 
49 aspirin Cox inhibitor 
50 Tadalafil  Inhibitor of PDE5 





DNA alkylating agent 
53 Naloxone HCl Antagonist of opioid receptors 
54 Hydrocortisone Agonist of glucocorticoid receptor 
55 Dexmedetomidine·HCl Agonist of alpha-2 adrenoceptor 
56 Eszopiclone  Interaction with GABAA receptors 
57 Regadenoson A2A receptor agonist 
58 Fomepizole Inhibitor of alcohol dehydrogenase 
59 Y27362 Rock inhibitor 
60 Ranolazine·2HCl P-gp inhibitor 
61 Niacin (Known As Vitamin 
B3, Nicotinic Acid And 
Vitamin Pp)  
Binds to niacin receptor, nicotinic acid 
phophoribosyltransferase and Nicotinate 
D-ribonucleoside pyrophosphate 
62 Doxapram·HCl H2O Inhibits potassium channel K2P 
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63 Tirofiban·HCl  Antagonist of GP IIb/IIIa receptor 
64 Iloperidone  D2 and 5HT2A receptor antagonist  
65 Fulvestrant Estrogen receptor antagonist 
66 Flucytosine Uracil analog, inhibits RNA synthesis 
67 hydroxocabalamin Vitamin B12a, cofactor of methionine 
synthase 
68 NS-1643 Ion channel inhibitor 
69 Nepafenac COX inhibitor 
70 Azathioprine Inhibitor of hypoxanthine-guanine 
phosphoribosyltransferase  
71 Dienogest Progesterone receptor agonist 
72 Ethosuximide  Inhibitor of T-type calcium channel subunit 
alpha 1G 
73 amoxicillin Inhibitor of PBP-1A 
74 sulfametoxazole Inhibitor of dihydropteroat synthase 
75 Bendamustine·HCl Alkylating agent; inhibits DNA synthesis 
76 Tolvaptan Vasopressin V1a and 2 antagonist 
77 Melphalan Alkylating agent; inhibits DNA synthesis 
78 Triptorelin Acetate Gonadotropin-releasing hormone receptor 
agonist 
79 Olsalazine·Na Thiopurine S-methyltransferase inhibitor 
80 Nitisinone 4-hydroxyphenylpyruvate dioxygenase 
inhibitor 
81 IKK 16 IKK inhibitor 
82 Auranofin NFKB inhibitor 
83 Calcitriol Vitamin D3 receptor antagonist 
84 Estradiol Estrogen receptor lapha agonist 
85 Pantoprazole  Potassium-transporting ATPase alpha 
chain1 inhibitor  
86 Eflornithine·HCl Ornithine decarboxylase antagonist 
87 Gsk690693 Akt1/2/3 inhibitor 
88 Rasagiline Mesylate Amine oxidase inhibitor 
89 Dalfampridine (4-
Aminopyridine) 
Inhibitor of potassium coltage-gated 
channels 
90 Rosiglitazone  PPAR-gamma receptor agonist 
91 Orlistat 
(Tetrahydrolipstatin) 
Inhibitor of pancreatic triacylglycerol lipase 
and fatty acid synthase 
92 Bortezomib Inhibitor of proteasome subunit beta 
93 Fluorouracil (5-
Fluorouracil) 
Inhibits DNA and RNA synthesis by 
inhibiting thymidylate synthase 
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94 Nateglinide Inhibitor of ATP-binding cassette 
95 Voriconazole Inhibitor of Lanosterol 14-alpha 
demethylase 




Ceramide glucosyltransferase inhibitor  
98 Decitabine DNA – methyltransferase 1 inhibitor 




Farnesyl pyrophosphate synthase inhibitor 
101 Blebbistatin Myosin inhibitors 
102 Tropicamide  Muscarinic acethylcholine receptor 
antagonist 
103 Anagrelide Inhibitor of cGMP-inhibited 3’,5’-cyclic 
phosphodiesterase A  
104 Azelaic Acid Inhibitor of Tyrosinase, 3-oxo-5-
beta/alpha-steroid 4-dehydrogenase 2 
105 Tacrine·HCl Acetylcholinesterase inhibitor 




Dopamine 2/3/4 receptor agonist  
108 Caffeine  Adenosine receptor A1/2a antagonist 
109 Valsartan Type 1 angiotensin II receptor antagonist 
 
